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English version 
The present study aims to investigate two different hypothesis: 
1) TNF- induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic 
HepG2 cell line, through the activation of suppressor of cytokine signaling 3 (SOCS3) 
Background. The suppressor of cytokine signaling (SOCS) proteins are negative regulators of the 
JAK/STAT pathway activated by pro-inflammatory cytokines, including the tumor necrosis 
factor- (TNF-). SOCS3 is also implicated in hypertriglyceridemia associated to insulin-
resistance (IR). Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) levels are frequently 
found to be positively correlated to IR and plasma very low-density lipoprotein-triglycerides 
(VLDL-TG) concentrations. Aim. The present study aimed to investigate the possible role of TNF-
 and JAK/STAT pathway on de novo lipogenesis and PCSK9 expression in HepG2 cells. Methods 
and results. TNF- induced both SOCS3 and PCSK9 in a concentration-dependent manner. This 
effect was inhibited by transfection with siRNA anti-STAT3, suggesting the involvement of the 
JAK/STAT pathway. Retroviral overexpression of SOCS3 in HepG2 cells (HepG2SOCS3) strongly 
inhibited STAT3 phosphorylation and induced PCSK9 mRNA and protein levels, with no effect on 
its promoter activity.  Consistently, siRNA anti-SOCS3 reduced PCSK9 mRNA levels while an 
opposite effect was observed with siRNA anti-STAT3. In addition, HepG2SOCS3 express higher 
mRNA levels of key enzymes involved in the de novo lipogenesis, such as fatty-acid synthase 
(FAS), stearoyl-CoA desaturase 1 (SCD-1), and apo-B. These responses were associated with 
significant increase of SCD-1 protein, activation of SREBP-1, accumulation of cellular TG and 
secretion of apoB. HepG2SOCS3 show lower phosphorylation levels of IRS-1 Tyr896 and Akt 
Ser473 in response to insulin. Finally, insulin stimulation produced an additive effect with SOCS3 
overexpression, further inducing PCSK9, SREBP-1, FAS and apoB mRNA. Conclusions. Our data 
candidate PCSK9 as a gene involved in lipid metabolism regulated by pro-inflammatory cytokine 
TNF-, in a SOCS3 dependent manner. 
2) Proprotein subtilisin/kexin type 9 (PCSK9) induces pro-inflammatory response in 
macrophages 
Background. Intraplaque release of inflammatory cytokines and chemokines from macrophages 
is directly implicated in atherogenesis, by inducing the proliferation and migration of media 
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smooth muscle cells (SMCs) to the neointima. PCSK9 is present and released by SMCs within the 
atherosclerotic plaque but its role within the vascular wall is still unknown. Aim. In the present 
study, we tested the hypothesis of a pro-inflammatory effect of PCSK9 on macrophages. 
Methods and results. The pro-inflammatory effect of PCSK9 was assessed on THP-1-derived 
macrophages, exposed to different concentrations (0.250 ÷ 2.5 µg/ml) of human recombinant 
PCSK9 (hPCSK9). After exposure for 24h to 2.5 µg/ml PCSK9, a significant induction of IL-1β 
(8.17±2.88 fold), IL-6 (36.4±19.3 fold), TNF-α (67.4±25.9 fold), CXCL2 (42.6±0.0 fold), and MCP1 
(17.0±6.8 fold), were observed. Importantly, physiological concentration of PCSK9 (0.250 µg/ml) 
also elicited a significant pro-inflammatory effect. Similar results were observed in human 
primary macrophages, where 2.5 µg/ml of hPCSK9 increased IL-1β (14.61±2.47 fold), IL-6 
(4.17±0.86 fold), TNF-α (4.51±2.08 fold), CXCL2 (2.58±0.26 fold), and MCP-1 (1.76±0.07 fold) 
gene expression and the released of TNF-α (+82.3%) and IL-6 (+41.8%) in cultured media, as 
determined by ELISA assay. Co-culture experiments of HepG2 overexpressing hPCSK9 and THP1 
macrophages also showed the induction of mRNA TNF-α (1.89±0.35 fold), IL-1β (2.03±0.29 fold), 
MCP-1 (4.82±1.26 fold) and CXCL2 (5.40±0.61 fold). Finally, the effect of hPCSK9 on TNF-α 
mRNA in murine LDLR-/- bone marrow macrophages (BMM) was significantly impaired as 
compared to wild-type BMM (5.44±0.28 fold vs 35.4±2.7 fold for LDLR-/- and wild-type, 
respectively). Conclusions. The present study provided evidences of a pro-inflammatory action 
of PCSK9 on macrophages, mainly dependent by the LDLR. The pathophysiological relevance of 
this effect still needs to be determined. 
Italian version: 
Il presente studio ha come scopo quello di verificare due diverse ipotesi: 
1) Il trattamento con TNF- induce l’espressione della proproteina convertase subtilisina 
kexina di tipo 9 (PCSK9) nella linea cellulare epatica HepG2, attraverso l’attivazione del 
soppressore del segnale delle citochine 3 (SOCS3)  
Introduzione. I soppressori del segnale delle citochine (SOCSs) sono proteine in grado di 
regolare negativamente la via del segnale JAK/STAT, a sua volta attivata dale citochine 
proinfiammatorie, tra cui il tumor necrosis factor- (TNF-). SOCS3, in particolare, risulta 
coinvolta nell’ipertrigliceridemia associata ad insulino resistenza (IR). Elevati livelli della 
Proproteina Convertasi Subtilisina Kexina di tipo 9 (PCSK9) sono stati frequentemente associati 
ad insulino resistenza e ad un’elevata concentrazione plasmatica di trigliceridi VLDL. Scopo: nel 
7 
 
presente studio è stato valutato il possibile ruolo del TNF- e della via del segnale JAK/STAT 
sulla de novo lipogenesi e sull’espressione di PCSK9, in cellule di epatocaricinoma umano 
HepG2. Metodi e risultati. Il trattamento con TNF- ha provocato un’induzione sia di SOCS3 che 
di PCSK9 in modo concentrazione-dipendente. Tale effetto risulta inibito in seguito a trasfezione 
con siRNA anti-STAT3, suggerendo il coinvolgimento della via del segnale JAK/STAT. La 
sovraespressione retrovirale di SOCS3 nelle cellule HepG2 (HepG2SOCS3) ha causato, come 
atteso, una forte inibizione della fosforilazione di STAT3 ed ha indotto l’espressione genica e 
proteica di PCSK9, senza alcun effetto sull’attività del suo promotore. Al contrario, la trasfezione 
con un siRNA anti-SOCS3 ha ridotto i livelli di RNA messaggero di PCSK9. Inoltre, le cellule 
HepG2SOCS3 presentano livelli più elevati dei principali enzimi coinvolti nella de novo lipogenesi, 
quali sintasi degli acidi grassi (FAS), stearoil-CoA desaturasi 1 (SCD-1) ed apo-B. Queste risposte 
risultano associate ad un significativo aumento anche dell’espressione proteica di SCD-1, 
nonché all’attivazione di SREBP-1, all’accumulo di trigliceridi all’interno della cellula ed alla 
secrezione di apoB. Le HepG2SOCS3 mostrano una minor fosforilazione del residuo tirosinico 896 
di IRS-1 e del residuo serinico 473 di AKT, in risposta all’insulina. Infine, lo stimolo con insulina 
produce un effetto additivo alla sovraespressione di SOCS3, inducendo ulteriormente 
l’espressione genica di PCSK9, SREBP-1, FAS e apoB. Conclusioni. Tali evidenze candidano PCSK9 
come gene coinvolto nel metabolism lipidico regolato dalla citochina proinfiammatoria TNF-, 
in maniera SOCS3 dipendente. 
2) La proproteina subtilisina/kexina di tipo 9 (PCSK9) induce una risposta pro-infiammatoria 
nei macrofagi 
Introduzione. Il rilascio di citochine e chemochine infiammatorie all’interno della placca 
aterosclerotica da parte dei macrofagi è direttamente implicata nell’aterogenesi, inducendo 
proliferazione e migrazione delle cellule muscolari lisce della tonaca media verso la neointima. 
PCSK9 viene secreto dalle cellule muscolari lisce all’interno della placca ma il suo ruolo sulle 
pareti del vaso è ancora sconosciuto. Scopo. Nel presente studio, abbiamo testato l’ipotesi di un 
possibile effetto pro-infiammatorio di PCSK9 sui macrofagi. Metodi e risultati. L’effetto pro-
infoammatorio di PCSK9 è stato testato in vitro su macrofagi THP-1-derivati, che sono stati 
esposti a diverse concentrazioni  (0.250 ÷ 2.5 µg/ml) di PCSK9 umana ricombinante (hPCSK9). 
Dopo un’esposizione di 24h alla concentrazione più elevata (2.5 µg/ml) di hPCSK9, è stata 
osservata un’induzione significativa dell’espressione genica di IL-1β (8.17±2.88 volte), IL-6 
(36.4±19.3 volte), TNF-α (67.4±25.9 volte), CXCL2 (42.6±0.0 volte) ed MCP1 (17.0±6.8 volte). 
Un’osservazione molto importante riguarda anche la concentrazione più fisiologica di PCSK9 
(0.250 µg/ml), in quanto anch’essa ha presentato un’attività pro-infiammatoria significativa. 
Simili risultati sono stati osservati anche in cellule macrofagiche umane primarie, dove la 
concentrazione 2.5 µg/ml di hPCSK9 ha portato ad un aumento dell’espressione genica di IL-1β 
(14.61±2.47 volte), IL-6 (4.17±0.86 volte), TNF-α (4.51±2.08 volte), CXCL2 (2.58±0.26 volte) ed 
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MCP-1 (1.76±0.07 volte), oltre ad un aumentato rilascio di TNF-α (+82.3%) ed IL-6 (+41.8%) nel 
medium di coltura, come determinato attraverso saggio ELISA. Ponendo i macrofagi THP-1-
derivati in co-coltura con cellule HepG2 sovraesprimenti PCSK9, si è osservata, ancora una volta, 
un’induzione dell’espressione genica di TNF-α (1.89±0.35 volte), IL-1β (2.03±0.29 volte), MCP-1 
(4.82±1.26 volte) e CXCL2 (5.40±0.61 volte). Infine, l’effetto di hPCSK9 sull’espressione genica di 
TNF-α in macrofagi di midollo osseo di topi LDL-/- è risultata significativamente ridotta se 
comparata a quella di macrofagi derivanti da topi wild-type (5.44±0.28 volte vs 35.4±2.7 volte 
per i macrofagi di topi LDLR-/- e wild-type, rispettivamente). Conclusioni. Il presente studio 
fornisce evidenze di un’azione pro-infiammatoria di PCSK9 sui macrofagi, principalmente 
dipendente dalla presenza del LDLR. La rilevanza fisiopatologica di questo effetto dovrà essere 
ulteriormente chiarita. 
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Abstract at a glance: 
 
 
 
Modified from: The new england journal of medicine “Mechanisms of disease Inflammation, 
Atherosclerosis, and Coronary Artery Disease” Göran K. et al. 
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Role of inflammation in atherosclerosis and metabolic disorders: 
Development of atherosclerosis 
Atherosclerosis is a chronic inflammatory disease of the vascular wall and it is the first cause of 
death in the Western World. The atherogenesis consists in a slow multifactorial process that 
results in development of atheromatous plaques within the arterial wall. The trigger factor is 
represented by a modification of cholesterol-containing low density lipoproteins (LDL) within 
the tunica intima. In particular, LDL particles undergo biochemical modification, like enzymatic 
attack or oxidation, with a consequent release of phospholipids, which promote a change in 
endothelial permeability and extracellular matrix composition beneath endothelium, leading to 
an increased penetration and retention of LDL particles in the artery wall 1,2. Endothelial cells 
increase their adhesion molecules, like vascular-cell adhesion molecule-1 (VCAM-1)3, and 
inflammatory genes expression, while modified LDL particles become able to induce leukocytes 
adhesion and macrophages endocytosis, causing intracellular cholesterol accumulation. 
Leukocytes migrate inside the tunica intima, the innermost layer of artery, following the 
chemoattractant mediators action. Once inside the arterial wall, monocytes (the most present 
white blood cells in the plaque) differentiate into macrophages, that phagocytes oxidized LDL, 
leading to the formation of foam cells, term given by microscope evidences of lipid-laden cells. 
Plaque macrophages also exert other inflammatory activities, characteristic of M1 
macrophages, by producing high amount of pro-inflammatory mediators, like interleukin-1β (IL-
1β) and tumor-necrosis factor-α (TNF-α). Atherosclerotic plaque formation also involves smooth 
muscle cells (SMCs), recruited from the tunica media, the middle layer of arterial wall. SMCs 
migrate to the tunica intima and proliferate in response to diverse stimuli, producing also 
elastin and collagen, the main components of extracellular matrix, and forming the fibrous cap 
that covers the plaque. Under the fibrous cap, lie macrophages-derived foam cells. Some of 
them are apoptotic cells that release their lipids, causing an extracellular accumulation. The 
impairment of efferocytosis, the clearance of dead cells, promotes accumulation of lipids and 
debris, forming the lipid-rich necrotic core of the plaque 4. The first clinical evidences of the 
presence of an atherosclerotic plaque are tissue ischemia, caused by flow-limiting stenosis, and 
detachment of thrombi after a physical disruption of the most thin, collagen-poor fibrous cap. 
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Figure A: Stages of atherosclerotic lesion development. a, the artery is composed by three 
layers. The inner one, called tunica intima, is lined by a monolayer of endothelial cells, in 
contact with blood, and contains resident SMCs. The middle one, or tunica media, is composed 
by a complex extracellular matrix of SMCs. The outer one, tunica adventitia, contains mast cells, 
nerve endings and microvessels. Physiologically, arteries are elastic, with demarcated laminae. 
b, the first atherosclerosis steps consist in blood leukocytes (mainly monocytes) adhesion to the 
activated endothelium and migration into the intima. Then occurs the maturation of monocytes 
in macrophages and their consequent accumulation of lipids, with the formation of foam cells. 
c, with the progression of the lesion, SMCs migrates from the tunica media from the intima, 
where they proliferate together with resident SMCs. Heightened synthesis of extracellular 
matrix components (collagen, elastin and proteoglycans) improves macrophages and SMCs 
death and consequent accumulation, forming the lipid core, or necrotic core. Cholesterol 
crystals and microvessels are typical of advanced plaques. d, the ultimate complication of 
atherosclerotic plaque is represented by thrombosis, a physical disruption of the fibrotic core of 
the plaque. Blood coagulation component come into contact with tissue factors inside the 
plaque, extending the thrombosis into the vessel lumen and blocking blood flow 5. 
14 
 
Future perspectives on atherosclerosis treatment: focus on inflammation 
During the last ten-twelve years, the evidences of the role of inflammation in atherosclerosis 
development and progression have grown and expanded. Many basic and clinical studies have 
underlined cellular and molecular mechanisms involved in the development of atherosclerosis 6. 
Several cell types derived from monocytes/macrophages, as several chemokines, cytokines and 
adhesion molecules, are implicated in atherogenesis, leading to the conclusion that 
atherosclerosis is not only a disorder caused by lipid accumulation, but it also has major 
inflammatory influences, that interact with atherogenic lipoproteins to accelerate disease 
progression, leading to plaque rupture and clinical events 5. In several animal models of 
atherosclerosis, indeed, inflammation evolves together with lipid accumulation in the artery 
wall. It is well known that modified lipids (like lipid hydroperoxides, lysophospholipids, carbonyl 
compounds and other active moieties localized in the lipid fraction of atheroma) can induce the 
expression of adhesion molecules, chemokines, proinflammatory cytokines and other mediators 
of inflammation in macrophages and vascular wall7-9.  Elevated values of circulating 
inflammatory markers usually accompany acute coronary syndrome and correlate with adverse 
prognosis and hospitalization, due to myocardial necrosis, ischemia-reperfusion damage, severe 
coronary atherosclerosis and primary inflammation10-17.  Inflammation not only has a pivotal 
role in the acute coronary syndrome, but also contributes to the development of 
atherosclerotic disease already in the earliest steps. Understanding that atherosclerosis is a 
disorder characterized by a low-grade vascular inflammation, can help us to predict future 
cardiovascular risk. Indeed, in large scale, population-based studies, it is shown that elevated 
levels of inflammatory mediators in apparently healthy people can have a predictive value for 
future vascular events. In particular, increased basal levels of proinflammatory cytokines, like IL-
6 and TNF-, are associated with an increased cardiovascular risk18-21.  Within the CANTOS 
Clinical Trial, a randomized, double-blind trial promoted by Novartis, it has been tested the 
efficacy of canakinumab, a monoclonal antibody targeting interleukin-1β, in the reduction of 
cardiovascular disease. Canakinumab, without affecting lipid levels, at a dose of 150 mg every 3 
months, led to a significantly lower rate of recurrent cardiovascular events, compared with 
placebo. This evidence demonstrates that reducing inflammation without affecting lipids levels, 
can reduce cardiovascular disease risk 22. Statins, pharmacological inhibitors of hydroxymethyl 
glutaryl coenzyme A reductase (HMG-CoA reductase), regulate LDL cholesterol pathway and are 
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still the first choice in the hypocholesterolemic therapy 23. They are characterized by a dual 
action: the decrease in LDL cholesterol levels is indeed accompanied with the inhibition of C-
reactive protein in human, and in large studies of these drugs it appears a clinical benefit due to 
an anti-inflammatory action, distinct from LDL cholesterol lowering 24,25. Despite the efficacy of 
statins, it remains a certain percentage of cardiovascular risk even in patients treated with 
them. It is estimated that the 20% of patients treated with the higher dose of statin will get into 
recurrent cardiovascular event within 2 or 3 years after an acute coronary syndrome26,27. For 
this reason, new pharmacological target are emerging, considering not only cholesterol 
pathways, but also inflammatory pathways.  
Obesity and low-grade subclinical inflammation 
Obesity is commonly associated with severe medical complications, including type 2 diabetes, 
insulin resistance, peripheral and coronary artery disease, stroke and heart failure. 
Complications of obesity are due to many events, such as vascular defects, endothelial 
dysfunctions, arterial stiffening and dysregulated adipose tissue signaling. Overnutrition leads 
to an increase in adipocytes number and size, resulting in adipose tissue expansion and 
macrophages infiltration. The presence of obese adipose tissue is frequently associated with a 
low-grade chronic subclinical inflammatory state 28, characterized by a persistent release of pro-
inflammatory cytokines, able to interact with inflammatory and immune pathways and to 
directly contribute to vascular dysfunction, through the activation of endothelium. In a 
condition of obesity, adipose tissue can increase the secretion of pro-inflammatory cytokines 
(TNF- and IL-6) by resident macrophages and, in addition, the secretion of hormones and 
chemokines is improved. All those factors are involved in energetic homeostasis and are 
strongly affected by a condition of metabolic dysregulation29. Between 1994 and 1995 
additional secreted factors, termed adipokines, were identified in adipocytes30,31. Adipokines, 
such as leptin, adiponectin, retinol binding protein 4 (RBP4) and resistin, interact with both 
central and peripheral tissues, in particular pancreas, hypothalamus, skeletal muscles, blood 
vessels, brain and liver, where they affect carbohydrate and lipid metabolism, inflammation, 
coagulation and blood pressure32-34. The dysregulation of adipokines secretion due to the 
expansion of adipose tissue in obesity is crucial in the development of metabolic diseases such 
as metabolic syndrome, insulin resistance, type 2 diabetes, vascular and heart diseases. 
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Focusing on the liver, it has been observed that pro-inflammatory adipokines, released by 
adipose tissue, can promote the hepatic synthesis of acute phase proteins, leading to 
hypercoagulability, pro-thrombotic state, oxidative stress, inflammation, endothelial 
dysfunction and impairment of glucose and lipid metabolism35. 
One of the mechanism behind adipokines activities, and in particular leptin activity, involves the 
JAK/STAT inflammatory pathway 36,37. 
 
 
FIGURE B: Effects of obesity-induced changes in adipokines secretion that lead to the 
development of systemic insulin resistance, metabolic syndrome, type 2 diabetes, and 
cardiovascular disorders. H.J. Harwood Jr. / Neuropharmacology 63 (2012) 57-75 
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JAK/STAT pathway: role on inflammation 
Signal transducer and activator of transcription (STAT) proteins:  
STAT proteins are involved in signal transduction and transcriptional activation and seven 
members compose the STAT family: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6. 
They present a common structure of five domains: the N-terminal domain, the supercoiled 
domain, the DNA-binding domain, the sec-homology-2 (SH2) domain and the C-terminal 
domain. The last one is, involved in transactivation and it contains a tyrosine residue, which 
promote the dimerization, and a serine residue, that, after phosphorylation, is involved in 
transcriptional activation38-40. STATs are cytoplasmic transcriptional factors, able to mediate 
cellular response to cytokines, adipokines, growth factors and hormones38-40, after the 
interaction with the respective receptor41.  
Figure C: The JAK/STAT pathway: a. Schematic representation of the JAK/STAT pathway. b. JAKs 
domain structure: JH1-7 domains present structural similarity in all the JAKs family, composed 
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by JAK1-3 and Tyrosine kinase 2 (TYK2); JH1, the kinase domain, contains two tyrosines that 
undergo phosphorylation after ligand binding to the receptor, while JH6 and 7 mediate JAKs-
receptors binding. c. STATs domain structure: the different modification that can occur on 
STATs structure can modulate these proteins activity. These modifications include tyrosine and 
serine phosphorylation, methylation (Met), ISGylation (ISG15), acetylation (Ace) and 
sumoylation (SUMO). d. Domain structure of SOCS family proteins: the SOCS box can bind to 
elongins B and C, known components of ubiquitin E3 ligase complex42,43. 
Modified from: Ke Shuai and Bin Liu. Nature 44 
 
The ligand interacts with its receptor on cell surface, causing its dimerization and the 
consequent activation of the associated JAK tyrosine kinases. The activated JAKs acts through 
the phosphorylation of specific receptor tyrosine residues, situated on the cytoplasmic domain 
of the receptor, which become suitable binding site for SH2-containing signaling proteins, like 
STATs. Once STATs protein interacts with phosphorylated tyrosine residues, in turn, they are 
phosphorylated by JAKs protein and undergo dimerization, leaving the cytokine receptor and 
translocating towards the nucleus, where they activate gene transcription, through the 
activation of the transcriptional factors sterol regulatory element binding proteins (SREBPs)39,45. 
STAT proteins promote fundamental cellular processes, like growth, differentiation, 
development, apoptosis, immunity response and inflammation 46,47. In particular, STAT3 
represents an important member of the family, since its aberrant expression is linked to cancer 
formation, transformation and progression. Dysregulated activation of STAT3 is very common in 
breast cancer, melanoma, prostatic cancer, myeloma, pancreatic, ovarian and cerebral cancers 
48,49. In addition to cancer development, with the regulation of cellular growth and apoptosis, 
STAT3 is involved in infections, immune disorders and in the development of atherosclerosis.  
The regulation of different STATs activities involves the amino-terminal region of these 
proteins50,51. The JAK/STAT pathway is finely regulated through different mechanism, one of 
which is represented by the negative feedback carried out by suppressor of cytokine signaling 
(SOCS) proteins. 
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Suppressor of cytokine signaling (SOCS) proteins 
Eight member composes SOCSs family: SOCS1-7 and CIS52,53. All the family members contains an 
SH2 domain, positioned between the amino-terminal and the carboxy-terminal domain, named 
SOCS box54. SOCS1,3 and CIS are the most studied for their activity on the JAK/STAT pathway 55. 
Physiologically expressed in all kind of cells, these proteins become rapidly induced by 
cytokines, through NF-B and STAT inflammatory pathways and they exert a negative-feedback 
control on JAK/STAT pathway56, inhibiting cytokines signaling. The mechanisms behind SOCSs 
activity are diverse, depending on the type of suppressor. For example, SOCS1 inhibits directly 
JAKs activity by binding to the activated JAKs, through its SH2 domain, while SOCS3 binds the 
activated receptor57-61. SOCS proteins may also be involved in the ubiquitin-proteasome 
signaling proteins degradation pathway42,43. A further control mechanism of the JAK/STAT/SOCS 
pathway occurs through SOCS proteins tyrosine phosphorylation by cytokines, at a post-
translational level, accelerating its degradation and regulating the JAK/STAT feedback 
inhibition62. SOCS1 and 3 present also a crucial role in immune function regulation. In particular, 
SOCS1 deficient mice die after few weeks after bird because of a fatal dysregulation of IFN-, 
after showing lymphopenia (caused by increased lymphoid organs apoptosis)63-66, while SOCS3 
knockout mice die before the birth67-69. Different studies have also assessed to SOCS3 the 
important role of IL-6 signaling negative regulation in macrophages. Both SOCS1 and 3 are 
induced by IL-6, TNF- 70 and IFN- and they can inhibit their responses71-73. SOCS proteins play 
an important role in the regulation of cardiovascular diseases, including heart failure, 
thrombosis and atherosclerosis. In particular, SOCS1 deficiency in macrophages leads to an 
increase in TNF- and IL-12 production, causing intravascular coagulation73,74. On the other 
hand, SOCS3 deficiency in macrophages lead to an enhanced anti-inflammatory activity of 
STAT3 and a consequent reduction of cytokines production73. Moreover, SOCS1 may also 
prevent atherosclerotic lesion in apoE-/- mice by suppressing IFN- signaling75, while in human 
atherosclerotic lesions, an increase in STAT3 phosphorylation is associated with a stable plaque 
phenotype76. It is also well known a correlation between SOCS proteins and cardiac dysfunction, 
where the induction of STAT3 by IL-6 cytokines family promote cardiac hypertrophy, as well as 
SOCS3 deficiency 77. SOCS1 and 3 are also involved in insulin signal, by blocking its intracellular 
signaling through the bind with insulin receptor, in IRS proteins site 78,79 and their high 
expression in the liver can generate insulin resistance in vivo 80. Even more important, SOCS3 
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suppression leads to a significant induction of liver steatosis, through the increase of SREBP-1 
expression and STAT3 phosphorylation, as compensatory effects. 
Sterol regulatory element binding (SREBPs) proteins 
The sterol regulatory element binding proteins (SREBPs) are a transcriptional factor family and 
represent key regulators of cholesterol and lipids biosynthesis. SREBPs precursors are 
synthetized in the endoplasmic reticulum81 and their structure is composed by four domains, 
with two transmembrane regions. The N-terminal domain of 480 amino acids represent the 
active portion, while the C-terminal domain makes a complex with the WD domain of another 
protein, called SCAP (SREBP cleavage activating protein), the SREBPs chaperone molecule. SCAP 
contains a sequence sensible to sterols, like HMG-CoA reductase82. SREBP activation is finely 
regulated by intracellular cholesterol levels. When intracellular cholesterol is high, SREBP is 
present in the endoplasmic reticulum in its inactive form, complexed with SCAP and with two 
other proteins, the insulin induced gene 1 and 2 (Insig1 and Insig2), responsible for the 
inhibition of SREBP translocation. As cholesterol levels decrease, Insig1 and Insig2 leave the 
SREBP-SCAP complex, which is included in endoplasmic vesicles (that present the COPII protein 
on the surface, recognized by SCAP), and translocated towards the Golgi apparatus. Here, the 
complex undergoes proteolytic cleavage by the protein convertase Subtilisin kexin isozyme/Site-
1 protease (SKI-1/S1P) and the intramembranous metalloprotease Site-2 protease (S2P). S1P 
and S2P frees the N-terminal domain of SREBP and the active SREBP goes in the nucleus, where 
it activates those genes involved in cholesterol and lipids biosynthesis and capitation82. While 
SREBP translocates in the nucleus, SCAP comes back in the endoplasmic reticulum, to create a 
complex with another SREBP protein. Recent studies demonstrated that SCAP directly binds to 
the cholesterol, through its sterol sensitive sequence, undergoing some conformational 
changes83, which make SCAP unable to interact with vesicles protein COPII84. By binding with 
SCAP, cholesterol also strengthen SCAP and Insig1-2 interaction.  These two actions lead to an 
inhibition of SREBP translocation in the Golgi. Insig1 represent the predominant isoform and its 
degradation is negatively regulated by sterols85. Once SREBP reaches the nucleus, its active 
portion binds to specific DNA sequences on target genes promotors, modulating their 
transcription. Most of these genes are involved in the cholesterol and fatty acids biosynthesis, 
like fatty acid synthase (FAS), Diglyceride acyltransferase (DGAT), HMG-CoA synthase and 
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reductase, Stearoyl-CoA desaturase (SCD) and LDL receptor and are induced by SREBP82. To 
date, three different isoform of SREBP have been identified: SREBP-1a, SREBP-1c and SREBP-2. 
SREBP-1a and 1c differs only in their N-terminal domain 81. SREBP-1a and SREBP-2 are the most 
expressed in cells, while organs (especially the liver) present higher amount of SREBP-1c and 
SREBP-286. The three isoforms differ for their in vivo functions. In particular, SREBP-1a strongly 
activates all those genes regulated by SREBP, including ones mediating cholesterol, triglycerides 
and fatty acids biosynthesis, while SREBP-1c and SREBP-2 seems to be more selective87. SREBP-
1c mainly regulates genes involved in fatty acids metabolism, while ones involved in cholesterol 
metabolism (HMG-CoA synthase and reductase) and uptake (LDL receptor) are regulated by 
both SREBP-1c and SREBP-287,88. 
 
 
Figure D: SREBP activation process. 
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Focus on SOCS3 role in obesity and insulin resistance 
Elevated levels of pro-inflammatory cytokines have been observed in obesity, infections and 
inflammation 89,90. In particular, TNF- plays a crucial role in insulin resistance in obese animal 
models 91 and elevated concentrations of IL-6 are associated with the development of type 2 
diabetes 92,93. The mechanism behind these observation includes the inhibited phosphorylation 
of insulin receptor and insulin receptor substrate 1 (IRS1) by TNF-, although this stimulus is too 
rapid to motivate the TNF- prolonged effect, suggesting the involvement of a transcription-
mediated regulation. Pro-inflammatory cytokines increase SOCS protein expression through 
STAT and NF-κB activation and, in particular, SOCS3 is able to bind to both insulin receptor and 
insulin-like growth factor 1 receptor 94-97, representing a link between elevated cytokine levels 
and decreased insulin sensitivity or insulin resistance. In 2004, Ueki et all, demonstrated that 
SOCS3 levels are increased in a condition of insulin resistance linked to obesity and that SOCS3 
binds to insulin receptor of cultured cells, through the interaction with Tyr960, inhibiting IRS1 
and IRS2 phosphorylation and, consequently, attenuating insulin signaling, glycogen synthesis 
and glucose transport, without inhibiting insulin receptor phosphorylation. SOCS3 leads also to 
a downregulation od PI 3-kinase and Akt 98. Moreover, SOCS3 mediates the inhibition of IRS 
phosphorylation, involving TNF--mediated inhibition of insulin signaling. Indeed, suppressing 
SOCS3 in 3T3L1 cells, the inhibition of tyrosine phosphorylation of IRS proteins by TNF- is 
partially attenuated and in db/db mice livers, where insulin resistance seems to be strongly 
mediated by TNF- , the reduction of SOCS3 partially normalizes IRS phosphorylation and 
hepatic steatosis 99. Summarizing, SOCS3 is increased in insulin-sensitive tissue in obesity and it 
can inhibit IRS1 and IRS2 phosphorylation, leading to insulin resistance. 
Proprotein convertase subtilisin kexin type 9 (PCSK9) 
Proprotein convertases (PCs) represent important bioactive molecules responsible for inactive 
proteins and peptides proteolysis in active forms. Since 1990 until 2000 have been identified 
eight PCs, responsible for many tissue-specific processing of secretory precursors100,101. 
Hormones, growth factors, receptors, metalloproteases, surface glycoproteins and membrane-
bound transcription factors are all substrates of PCs, depending on their site of action and 
protease activity, and undergo activation or inactivation102-104. Seven of PCs members belongs 
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to the kexin subfamily, which has a specific cleavage affinity for basic sites. The proprotein 
convertases that belong to the kexin family are furin, PC1/3, PC2, PC4, PACE4, PC5/6 and 
PC7/LPC 104-106, while S1P belongs to the pyrolysin subfamily of subtilase107. This one cleaves 
nonbasic amino acidic residues. The proprotein convertase subtilisin kexin type 9 (PCSK9) is the 
ninth and last member of mammalian PCs, discovered in 2003 by Dr Nabil G. Seidah and his 
research group at the Laboratory of Biochemical Neuroendocrinology of the Institute de 
Recherché Cliniques de Montréal, Canada. First identified as neural apoptosis-regulated 
convertase 1 (NARC-1) by two different pharmaceutical companies (Millennium 
Pharmaceuticals, Cambridge, MA, Patent no. WO 01/57081 A2 and Eli Lilly, Patent no. WO 
02/14358 A2) in primary cerebellar neurons, PCSK9 was classified in the proteinase K subfamily 
of subtilase108. The structure of this proprotein consist in 692 amino acids organized in a 
structure similar to others family members: a signal peptide, a prodomain, a subtilisin-like 
catalytic domain and a C terminal domain, which differs from other family members one109. 
PCSK9 exert its catalytic activity through the catalytic triad Asp186, His226 and Ser386108,110,111. 
PCSK9 is produced as a soluble zymogen (pre-proPCSK9) that undergoes autocatalytic 
processing in the endoplasmic reticulum 112, to obtain the inactive heterodimer proPCSK9, 
composed of a prodomain fragment (14-kDa) and a mature fragment (57-kDa), which contains 
the C-terminal domain and the catalytic one 113. The prodomain has an important function in 
the correct secretion and folding of the protein114-116. PCSK9 has been discovered in the brain, 
but almost all the circulating PCSK9 derives from the liver117. A significant amount of circulating 
PCSK9 is associated with LDL, HDL and VLDL 118 and it is present at different concentrations, 
depending by individual health, sex and age, presenting a minimum of 33ng/ml and a maximum 
of 2988ng/ml 119. PCSK9 median levels are higher in women plasma (517ng/ml) then in men 
(450ng/ml)119. Despite its predominant liver derivation, some analysis on adult mice show that 
PCSK9 is also synthetized and secreted by other tissues, like kidney, cerebellum, small intestine 
108, perigonadal fat 120, aorta and pancreatic islets 121. Recently, our research group 
demonstrated the presence of PCSK9 also in human atherosclerotic plaque122. About cell 
culture, PCSK9 is highly expressed in human hepatocytes but also in smooth muscle cells, 
endothelial cells 122,123 and colonic enterocyte-like cells 124, while monocytes and macrophages 
do not express the protein 122,125.  
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Transcriptional regulation of PCSK9:  
Similarly to other genes involved in cholesterol homeostasis regulation, PCSK9 is 
transcriptionally regulated by the SREBPs family126. There are many evidences of an induction of 
PCSK9 after the administration of statins, the HMG-CoA reductase inhibitors, due to the 
activation of SREBP pathway.  
PCSK9 seems to be regulated by both SREBP-1c and 2. The role of SREBP-1c in PCSK9 regulation 
has been observed in both mice and humans, where PCSK9 is increased in the presence of 
insulin and is positively correlated with insulin resistance, liver steatosis and VLDL-TG, 
respectively126-130. According to these observations, PCSK9 appears to be not only an important 
regulator of LDL cholesterol, but also of the triglycerides-rich lipoproteins. Very interesting, it is 
known that PCSK9 levels are only weakly associated with LDL cholesterol levels, while the 
correlation is stronger between PCSK9 and triglycerides, glucose and insulin plasma 
levels119,127,131,132.  
Involvement of PCSK9 in autosomal dominant hypercholesterolemia:   
Autosomal dominant hypercholesterolemia (ADH) is a lipid metabolism disorder that induce a 
strong increase in plasma levels of LDL-cholesterol. This hereditary condition produces different 
symptoms, ranging from skin xanthomas and arcus corneae to fatal cardiovascular 
complications133,134. There are three important genes involved in ADH: LDL receptor gene 135, 
APOB gene 136 and a third gene, recognized as PCSK9 137,138. In 2003, two different mutations in 
PCSK9 gene were identified in a French family and associated with the ADH disease. These were 
the S127R and the F216L, two dominant “gain of function” mutations112,139. Subsequently, three 
“loss of function” mutation of PCSK9, the Y142X, the C679X and the R46L, were discovered in a 
group of 13,761 patients which presented lower total cholesterol, LDL cholesterol and 
triglycerides levels, 140. The mechanism that allows PCSK9 to be linked with ADH is hide in its 
capability do bind to LDL receptor and, consequently, causing its degradation141-144. PCSK9 is 
rapidly processed from its precursor form of 74-kDa to the mature form of 60-kDa, then 
secreted from the cell145. Plasma PCSK9 interacts directly with LDL receptor, present on cell 
surface, and undergoes internalization together with the receptor. The internalized complex 
reach the endocytic-lysosome subcellular compartments145,146. LDL receptor can be also 
degraded through another pathway, the post-ER compartments125.  
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PCSK9 – LDL receptor interaction: 
Further studies have identified the molecular portion of PCSK9 able to interact with LDL 
receptor. Through the in vitro deletion of different portion of LDL receptor (epidermal growth 
factor-like repeat-A, B and C), Zhang and his research group discovered that PCSK9 binds to the 
EGF-A domain of LDL receptor147. Moreover, this bind resulted dependent by pH conditions, 
becoming significantly tighter at pH 5.2 compared with neutral pH147. PCSK9 has a lower affinity 
to the LDL receptor. It is hypothesized that LDL and VLDL particles can cause a conformational 
change in LDL receptor, reducing the affinity with PCSK9, compared to LDL particles; moreover 
PCSK9 serum levels are lower than LDL particles. 148. In Figure E and F is shown the complex 
interaction between PCSK9 and LDL receptor and the mechanism behind the receptor 
degradation, mechanism that does not involve PCSK9 proteolytic activity113. 
 
Figure E: PCSK9/LDL receptor complex structure. Pro (blue): PCSK9 prodomain, Cat (red): 
catalytic domain, CTD (brown): C-terminal domain; LDLR receptor domains are L7 (beige), EGF-A 
(yellow), EGF-B (green) and EGF-C/β-propeller (cyan). Spheres indicate Ca2+ ions. In the box is 
represented the interaction between β-propeller of LDL receptor and PCSK9 prodomain148. 
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Figure F: Possible mechanism of interaction between PCSK9 and LDL receptor. A. at neutral 
pH, the L7 domain of LDL receptor on cell surface adopts open extended form and binds to LDL 
particle through the ligand-binding domain (gray circles). B. inside the endosome, where the pH 
is lower, LDL receptor closes its structure, releases LDL particle and undergoes recycling. C. 
PCSK9 binds to LDL receptor through the EGF-A domain through its catalytic domain, while its 
prodomain restrains EGF-B/β-propeller flexibility. PCSK9 C-terminal domain (CTD) may interact 
with a co-receptor that promotes or inhibits PCSK9-LDL receptor interaction. D. Inside the 
endosome, in this case, the lower pH enhances PCSK9/LDL receptor affinity, preventing the 
complex dissociation and the consequent receptor recycle. LDL receptor undergoes lysosomal 
degradation148-151.  
Association between PCSK9 mutant variants and LDL cholesterol plasmatic levels: 
As hinted before, the first clue of the existence of PCSK9 genetic variants was found in a French 
family affected by ADH. All the three-generation members affected by the disease showed 
elevated total cholesterol plasma levels138. In particular, LDL cholesterol levels reached 
concentrations of 236 mg/dl and 312 mg/dl respectively for 17 and 40 years old members138. 
The discovery of the first PCSK9 mutation (S127R), through positional cloning analysis, was 
followed by the observation of a second mutation (F216L). Both were characterized as gain of 
function mutations. The mechanisms behind the correlation between these mutations and ADH 
disease involves both LDL receptor degradation and PCSK9 structure152. PCSK9 affinity with LDL 
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receptor, is indeed increased in the presence of the S127R mutation 110,150, leading to an 
improved receptor degradation 153, while for the F216L it has been demonstrated a higher 
resistance of the RFHR218 PCSK9 motif to furin cleavage 110,154,155, leading PCSK9 to an improved 
stability. However, the strongest gain of function mutation of PCSK9 was identify in Norwegian 
and Utah subjects with a diagnose of familial hypercholesterolemia (FH) 156,157. This mutation 
(D374Y) enhances binding affinity with LDL receptor at both neutral and acid pH conditions. 
There are also some loss of function PCSK9 mutations, associated with low LDL cholesterol 
serum levels. For example, Dallas Heart Study (performed on Afro-Americans, European-
Americans, Hispanics and other ethnicities) 158 identified two different PCSK9 loss of function 
mutations (C426G and C2037A) in Afro-American population 159. Moreover, diverse healthy 
persons with PCSK9 null allele homozygosis had been characterized. These people present 14 
mg/dl of LDL cholesterol and they do not present any particular disease, like their children160. 
Another PCSK9 loss of function mutation was discovered from Italian patients affected by 
hypobetalipoproteinemia, which presented very low LDL cholesterol levels161. 
Role of PCSK9 in insulin resistance, VLDL cholesterol and triglycerides metabolism 
After the observation of how a PCSK9 loss of function mutation can results in a strong decrease 
in cardiovascular risk, the next question was if PCSK9 negative effect on LDL cholesterol 
metabolism was only due to the LDL receptor degradation, or if the VLDL receptor could also be 
involved. Individuals with gain of function mutation of PCSK9 presented high levels of VLDL, 
triglycerides and apoB100, ascribable to a higher production of VLDL by the liver162. Moreover, 
fasting PCSK9 levels are positively correlated with fasting serum triglycerides levels163. It was 
also demonstrated that PCSK9 increases VLDL triglycerides and ApoB production rate163, 
apparently with a mechanism that involves a direct increase of VLDL secretion rate by the liver, 
through the degradation of LDL receptor. Indeed, ApoB is a VLDL component, required for their 
hepatic assembly and secretion, moreover LDL receptor promotes ApoB post-translational 
degradation in a proteasome-dependent way164,165, reducing VLDL secretion. In addition, PCSK9 
seems to be responsible also for a decreased apoB100 degradation rate166, mainly in the 
presence of LDL receptor. An addition mechanism can be the autofagosome/lysosome 
pathway166, since lower ApoB levels were observed in hepatocyte autofagosomes of animals 
with overexpression of PCSK9166. It is thought that PCSK9 can deviate ApoB from its 
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degradation, making it available for VLDL synthesis. In human elevated levels of PCSK9 are also 
correlated with insulin resistance and it has been observed that the inhibition of insulin 
receptors expression causes an increase in PCSK9 hepatic expression130,132,167. 
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AIM OF THE STUDY (I) 
 
The previous evidences link obesity with a low grade sub-clinical inflammation, responsible for 
an impaired glucose and lipid metabolism 29, 32, 34. The secretion of pro-inflammatory proteins 
from the adipose tissue, indeed, leads to the activation of JAK/STAT/SOCS pro-inflammatory 
intracellular pathway, involved in inflammation, hypertriglyceridemia and insulin resistance 46, 
47. Recent evidences demonstrated also the involvement of PCSK9 in insulin resistance 130-132, 167 
and lipid metabolism 162, 163, suggesting a possible correlation between the JAK/STAT/SOCS 
pathway activation and PCSK9. The present study aimed to investigate the possible role of the 
pro-inflammatory protein TNF- and the JAK/STAT pathway on de novo lipogenesis and PCSK9 
expression in human HepG2 cell line, through the activation of SOCS3. 
  
Modified from: 
Ueki K. Et al; PNAS 2004.;101: 
10422-7 
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MATERIAL AND METHODS (I) 
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Cell cultures 
The Human hepatocellular liver carcinoma cell line, HepG2, was cultured in 10%FCS/MEM 
supplemented with penicillin (10,000 U/ml), streptomycin (10 mg/ml), nonessential amino acids 
and sodium pyruvate. For the experiments, cells were incubated with MEM containing either 
10% of lipoprotein plasma deprived serum (LPDS) or 10% Fetal Calf Serum (FCS), as indicated in 
the figures legend. 
Reagents and antibodies 
MEM, trypsin EDTA, penicillin, streptomycin, nonessential amino acid solution, FCS, disposable 
culture flasks and petri dishes were from Euroclone (Pero, Milan, Italy), and filters were from 
Millipore (Billerica, MA). Molecular weight protein standards were from BIO-RAD Laboratories 
(Hercules, CA). SDS, TEMED, ammonium persulfate, glycine, and acrylamide solution (30%T, 
2.6%C) were obtained from BIO-RAD Laboratories. BCA assay for determination of protein 
concentrations was purchased from Thermo Fischer Scientific (Waltham, MA). [14C]-Acetate 
were from Amersham (Cologno Monzese, Milan, Italy). Recombinant insulin, Tumor Necrosis 
Factor- (TNF-) and bovine serum albumin (BSA) were purchased from SIGMA-Aldrich (Milan, 
Italy). STAT3 inhibitor, MD77, was kindly provided by Prof. Daniela Barlocco (University of 
Milan, Milan, Italy). The JAK inhibitor JAK1 was purchased from Millipore (Millipore, Milan, 
Italy). For Western Blot (WB) analysis, the following antibodies were used: anti-PCSK9 (Cayman, 
Tallinn, Estonia), anti-α-tubulin (SIGMA-Aldrich), anti-pAKT (Millipore); anti-AKT and anti-SOCS3 
(Cell Signaling Technology, Denver, MA); anti-pSTAT3, anti-insulin receptor substrate (pIRS-1) 
and anti- stearoyl-CoA desaturase (SCD-1) (Abcam, Cambridge, UK); anti-STAT3 and SREBP-1 
(Santa-Cruz Biotechnology, Santa Cruz, CA); anti-mouse and anti-rabbit peroxidase-conjugated 
secondary antibodies (Jackson ImmunoResearch Lab; Cambridgeshire, UK).  
Animals 
Four-week-old male ob/ob mice and their lean, wild-type male C57BL/6J controls were 
purchased from Charles River (Calco, Italy). In compliance with the Principles of Laboratory 
Animal Care (NIH publication 86-23), mice were housed at constant room temperature (23°C) in 
a 12-hour light/dark cycle (7 a.m. to 7 p.m.) receiving standard chow and water ad libitum. Mice 
were sacrificed at fourteen weeks of age in the fasted state. 
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Generation of human SOCS3 expression construct and retroviral infection in HepG2 cells 
Full-length human SOCS3 (accession no. 003955) was generated by polymerase chain reaction 
(PCR) using the following primers: 5’-CGGGATCCATGGTCACCCACAGCAAGTTTCC-3’ 
and 5’-CGCTCGAGTTAAAGCGGG GCATCGTACTGG-3’and the Expand High-Fidelity PCR 
System (Roche Diagnostics, S.p.A, Monza, Italy). The sequence of the polymerase chain reaction 
generated construct was confirmed by sequencing (Primm, Milan, Italy). Retroviral expression 
plasmid was then constructed using the pBM-IRES-PURO 
168
 expressing the puromycin 
resistance gene as a selectable second cistron gene, generated from the original pBM-IRES-
EGFP, generously provided by Garry P. Nolan (Stanford University, Stanford, CA). Retroviral 
infections of HepG2 were performed as previously described 
168
. A polyclonal population of 
HepG2 control and SOCS3 overexpressing cells have been than selected with 10 μg/ml of 
puromycin. 
Transfection of siRNA 
ON-TARGET plus SMART pool siRNA directed to STAT3 and SOCS3 or scramble control were 
purchased from DharmaconTM (Carlo Erba Reagents, Milan, Italy). Transfections were 
performed as previously described using SilentFectTM Lipid Reagent (BIO-RAD laboratories, 
Hercules, CA) according to the manufacturer’s protocol 169,170. HepG2 cells were seeded at a 
density of 6×105/well (6 well tray) the day before the transfection in completed medium. Cells 
were then transfected with 20 nM of siRNA for 48h then the medium replaced with MEM 
containing 5%LPDS ± TNF-
WB analysis.   
Synthesis of total cholesterol 
Cholesterol biosynthesis was estimated by measuring the incorporation of [14C]-Acetate into 
cellular cholesterol, as previously described171.  
Evaluation of intracellular triglycerides and cholesterol levels 
Total cellular lipids were extracted with hexane/isopropanol 3:2 and TG and Cholesterol 
contents were determined with enzymatic assays (HORIBA ABX, Montpellier, France). 
33 
 
ELISA assay 
Conditioned media was cleared by centrifugation (13,000 rpm for 10 min.) and store at -20°C. 
The amount of apolipoprotein (Apo) B (Vinci-Biochem, Firenze, Italy) and PCSK9 (R&D System, 
Minneapolis, MN) was then quantified by using the ELISA assays according to manufacturer’s 
instructions. The values were normalized with total cell protein contents, extracted from the 
cell monolayer, determined by BCA assay (Thermo Fischer Scientific).  
Luciferase reported promoter activities assay 
The plasmid pGL3-PCSK9-D4 contains the 5′-flanking region of the PCSK9 gene from -440 to -94, 
relative to the ATG start codon as previously described172. To measure the PCSK9 promoter 
activity, HepG2 cells were seeded in 48 well plates at a density of 8×105 cells per well. On the 
next day, cells were transiently transfected with pGL3-PCSK9-D4 plasmids with turbofect 
reagent (Carlo Erba Reagents) and, 48h post transfection, cells were incubated with serum-free 
medium in the presence or absence of insulin (10-7M) for an additional 24h. Luciferase 
activities were measured by using Neolite reagent (Perkin Elmer, Milan, Italy) according to 
manufacturer’s instructions. pCMV-β vector, encoding for β-galactosidase, (Clontech Lab., 
Mountain View, CA) was cotransfected as internal control. Β-galactosidase activity was assayed 
as described173. Luciferase activity was normalized to the β-galactosidase activity of the co-
transfected pCMV-β construct. 
RNA preparation and quantitative real time PCR 
Total RNA was extracted with the iScript Sample Preparation Buffer (BIO-RAD laboratories) 
cDNA synthesis preparation reagents (BIO-RAD laboratories) according to manufacturer’s 
instructions. Reverse transcription-polymerase first-strand cDNA synthesis was performed by 
using the iScript cDNA synthesis Kit (BIO-RAD laboratories). Quantitative real time PCR (qPCR) 
was then performed by using the Kit Thermo SYBR Green/ROX qPCR Master Mix (Carlo Erba 
Reagents) and specific primers for selected genes. Primer sequences used for qPCR analysis are 
shown in Table 1. The analyses were performed with the ABI Prism® 7000 Sequence Detection 
System (Applied Biosystems; Life Technologies Europe BV, Milan, Italy). PCR cycling conditions 
were as follows: 94°C for 3min, 40 cycles at 94°C for 15s, and 60°C for 1min. Data were 
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expressed as Ct values and used for the relative quantification of targets with the ΔΔCt 
calculation. 
Table 1. Primer sequence utilized for the qPCR analysis. 
Western Blot Analysis 
Total cytosolic protein extracts of HepG2 and HepG2SOCS3, were obtained by collecting cells in 
150 μl of Mammalian Protein Extraction Reagents (Thermo Fisher Scientific) containing a 
cocktail of protease and phosphatase inhibitors (Roche Diagnostics). Twenty µg of proteins and 
a molecular mass marker (Novex® Sharp Protein Standard, InvitrogenTM; Life Technologies 
Europe BV) were separated on 4-12% sodium dodecylsulfate-polyacrylamide gel (SDS-PAGE; 
Novex® NuPAGE® 4-12% Bis-Tris Mini Gels, InvitrogenTM; Life Technologies) under denaturing 
and reducing conditions. Proteins were then transferred to a nitrocellulose membrane by using 
the iBlotTM Gel Transfer Device (InvitrogenTM; Life Technologies). The membranes were 
washed with Tris-Buffered Saline-Tween 20 (TBS-T) and non-specific binding sites were blocked 
in TBS-T containing 5% (BSA; Sigma-Aldrich) for 90 min at RT. The blots were incubated 
overnight at 4°C with a diluted solution (5% BSA or non-fat dried milk) of the following human 
primary antibodies: anti-PCSK9 (1:100) anti-pAKT, (1:100); anti-AKT (1:1,000); anti-pSTAT3 
Primer Forward Reverse 
18S 5’-CGGCTACCACATCCACGGAA-3’ 5’-
CCTGTATTGTTATTTTTCGTCACTACC-3’ 
   
Human   
Fatty Acid 
synthase 
5’-GCAAATTCGACCTTTCTCAGAAC-3’ 5’-GGACCCCGTGGAATGTCA-3’ 
HMG-CoA 
reductase 
5’-CTTGTGTGTCCTTGGTATTAGAGCTT-3’ 5’-GCTGAGCTGCCAAATTGGA-3’ 
SOCS3 5’-GACCAGCGCCACTTCTTCAC-3’ 5’-CTGGATGCGCAGGTTCTTG-3’ 
SREBP-1 5’-CGGAACCATCTTGGCAACA-3’ 5’-GCCGGTTGATAGGCAGCTT-3’ 
SREBP-2 5’- AGCTGGTCTGTGAAG-3’ 5’- CGCAATGGGGTCAGC-3’ 
LDLR 5’-GTGTCACAGCGCCG-3’ 5’-CGCACTCTTTGATG-3’ 
PCSK9 5’-CCTGCGCGTGTCAACT-3’ 5’-GCTGGCTTTTCCGAAACTC-3’ 
SCD-1 5’-CTATACCACCACCACCACCA-3’ 5’-GGGCATCGTCTCCAACTTAT-3’ 
apoB 5’-GCAGACTGAGGCTACCATGA-3’ 5’-AGGATTGTTCCGAGGTCAAC-3’ 
   
Mouse   
PCSK9 5’- AACCTGGAGCGAATTATCCCA-3’ 5’- TTGAAGTCGGTGATGGTGACC-3’ 
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(1:10,000); anti-pIRS-1 (1:5,000); anti-SCD-1 (1:500); anti-STAT3 (1:1,000); anti-SREBP-1a 
(1:500); anti-SOCS3 (1:100); anti-HMG-CoA reductase (1:500); and anti-α-tubulin (1:2,000). 
Membranes were washed with TBS-T and then exposed for 90 min at RT to a diluted solution 
(5% non-fat dried milk) of the secondary antibodies. Immunoreactive bands were detected by 
exposing the membranes to ClarityTM Western ECL chemiluminescent substrates (Bio-Rad 
Laboratories) for 5 min and images were acquired with a ChemiDocTM XRS System (Bio-Rad 
Laboratories). Densitometric readings were evaluated using the ImageLabTM software as 
previously described174. The values of the phosphorylated proteins were normalized to those of 
the corresponding constitutive forms to express arbitrary units of relative expression. 
Analysis of data 
Statistical analysis was performed using the Prism statistical analysis package version 6.0 
(GraphPad Software, San Diego, CA). Data are given as mean ± SD of three independent 
experiments. When possible, p-values were determined by Student’s t-test. Otherwise, 
differences between treatment groups were evaluated by 1-way ANOVA. A probability value of 
p<0.05 was considered statistically significant. 
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RESULTS (I) 
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TNF- induces SOCS3 and PCSK9 in HepG2 cells 
Release of pro-inflammatory cytokines, such as TNF-α and IL-6, from adipocytes of obese 
subjects with IR, has been shown to activate the JAK/STAT pathway at the hepatic levels and 
inducing, either directly or indirectly, the transcription of different target genes including SOCS 
proteins (6,7). In agreement with these observations, we found that the incubation of hepatic 
cell line HepG2 with TNF-α induced the expression of SOCS3 mRNA in a time- and 
concentration-dependent manner (Figure 1A), reaching the maximal induction after 24h 
incubation at the concentration of 10 ng/ml. This latter resulted in three-fold induction of 
SOCS3 protein, evaluated by WB analysis (Figure 1B). Under the same experimental conditions, 
TNF- induced PCSK9, although to lower extent (Figure 1C). Transfection of HepG2 cells with 
specific siRNA significantly down-regulated protein expression of STAT3 and SOCS3 (Figure 1D). 
siRNA STAT3 completely blocked the induction of SOCS3 by TNF- (Figure 1E). A similar effect 
was observed on the expression levels of PCSK9, where siRNA to either SOCS3 or STAT3 blocked 
the effect of TNF- (Figure 1F). These results suggest the possibility that TNF- induces PCSK9 
by inducing the SOCS3 expression.   
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FIGURE 1. TNF- induces SOCS3 and PCSK9 in HepG2 cells. A and C) HepG2 cells were seeded 
in MEM/10% FCS and the day after incubated with MEM supplemented with 10% LPDS for 6h 
and 24h in the presence or absence of different concentrations of TNF- (0.1, 1 and 10 ng/ml). 
At the end of the incubation, the total RNA was extracted and mRNA levels of SOCS3 and PCSK9 
were determined by qPCR. B) SOCS3 protein expression was evaluated by WB analysis from 
total protein extracts of HepG2 cells incubated for 24h with 10 ng/ml of TNF-. α-tubulin was 
used as loading control. D) HepG2 cells were seeded in MEM/10% FCS and the day after 
transfected with siRNA scramble, STAT3 and SOCS3. After 48h, the medium was replaced with 
MEM with 10% LPDS. After an additional 24h, the protein expression of STAT3 and SOCS3 and 
α-tubulin were evaluated by WB analysis. E and F) The cells were incubated under the same 
experimental conditions described for panels A-C, in the presence or absence of 10 ng/ml TNF- 
Basal TNF-α 10ng/ml 
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during the last 24h of incubation in MEM with 10% LPDS. At the end of the incubation, the total 
RNA was extracted and mRNA levels of SOCS3 and PCSK9 were determined by qPCR. 
Differences between treatments were assessed by Student’s t-test (A, B, C) or 1-way ANOVA (D, 
E, F), *p<0.05; **p<0.01; ***p<0.001. 
SOCS3 overexpression induces PCSK9 in HepG2 
To further investigate the role of SOCS3 on PCSK9 expression, we generated a retrovirally 
transduced HepG2 cell line with a plasmid encoding human SOCS3 (HepG2SOCS3). After 
puromycin selection, the mRNA and protein overexpression of exogenous human SOCS3, were 
evaluated by qPCR and WB analyses, respectively. HepG2SOCS3 cells were compared with HepG2 
transduced with empty retroviral vector encoding only the puromycin resistance gene. As 
shown in Figure 2A, retroviral transduction determined approximately 90-fold induction of 
mRNA of SOCS3 that translated into a 2~5 fold increase of protein SOCS3 (Figure 2B). The 
overexpression of SOCS3 abrogated basal STAT3 phosphorylation state (Figure 2C). HepG2SOCS3 
cells show higher levels of PCSK9 mRNA (3.48±0.35 fold, Figure 2D) and increased amount of 
cellular and secreted PCSK9 (1.53 fold and 2.18±0.38 fold respectively; Figure 2E and 2F). Since 
SOCS3 has been shown to be up regulated in animal models of obesity (6), we then evaluated 
the mRNA levels of PCSK9 and SOCS3 in the liver of ob/ob and wild type C57BL/6 control mice. 
The ob/ob mice expressed higher levels of SOCS3 (6.46±4.8 fold) and this condition was 
associated with a significant induction of PCSK9 (2.03±1.54 fold) (Figure 2G and 2H). The 
inhibition of SOCS3 and STAT3 by siRNA resulted in an opposite effect on PCSK9 mRNA levels, 
with a significant reduction after transfection with siRNA SOCS3 and an induction with siRNA 
STAT3 (Figure 2I). We then investigated the effect of SOCS3 on PCSK9 promoter activity in 
HepG2 and HepG2SOCS3 transfected with the luciferase reporter construct pGL3-PCSK9-D4 (32). 
This plasmid contains the 5′ flanking region of the PCSK9 gene, from nt -440 to -94 (relative to 
the ATG start codon), in front of the luciferase coding sequence. The relative luciferase activity 
of the PCSK9 promoter was not affected by the expression of SOCS3 in HepG2 cells (Figure 2L).  
A similar response was observed by using the D4 construct containing the mutation of sterol 
regulatory element (SRE), while the mutation of hepatocyte nuclear factor (HNF)-1 site 
determined a significant increase of the promoter activity in HepG2SOCS3 cells, although the 
overall transcriptional activity was almost abolished (Figure 2L). 
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FIGURE 2. SOCS3 overexpression induces PCSK9 in HepG2 cells. A) HepG2 cells were 
retrovirally transduced with empty retroviral vector or encoding for human SOCS3. After 
puromycin selection, the expression of SOCS3 mRNA was evaluated by qPCR in HepG2 and 
HepG2SOCS3 cultured in MEM supplemented with 10% LPDS for 24h. B) Under the same 
experimental conditions, SOCS3 expression was determined by WB analysis from total cell 
lysates using an anti-SOCS3 antibody. The membrane was stripped and re-probed with anti--
tubulin antibody as loading control. C) WB analyses with anti-phospho-STAT3 and anti-STAT3 
were performed from the same samples described for panel B. D-F) HepG2 and HepG2SOCS3 
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cells were seeded in MEM/10%FCS and the day after incubated with MEM containing 10%LPDS 
for 24h. D) PCSK9 mRNA was determined by qPCR. Intracellular (E) and secreted (F) PCSK9 levels 
were evaluated by WB analysis and ELISA assay, respectively. For the determination of PCSK9 
levels with WB analysis, the cells were incubated for 24h under serum-free condition. G and H) 
PCSK9 and SOCS3 mRNA expression levels (qPCR) were determined from total hepatic RNA of 
male ob/ob (n=5) and C57BL/6 control mice (n=5). I) HepG2 cells were seeded in MEM/10% FCS 
and the day after transfected with siRNA scramble, SOCS3 and STAT3. After 48h, the medium 
was replaced with MEM with 10% LPDS. After an additional 24h, the total RNA was extracted 
and mRNA levels of PCSK9 were determined by qPCR. L) HepG2 and HepG2SOCS3 cells were 
transfected with pGL3-PCSK9-D4 or pGL3-PCSK9-SREmut or pGL3-PCSK9-HNFmut. The day after 
the transfection the medium was replaced with MEM containing 10%LPDS and, after an 
additional 24h, luciferase activities were determined by Neolite reagent. Luciferase activities 
were normalized to the β-galactosidase activity of the cotransfected pCMV- construct. 
Differences between groups were assessed by Student’s t-test (A-H) or 1-way ANOVA (I, L) 
*p<0.05; **p<0.01. 
Pharmacological inhibition of JAK/STAT pathway induces PCSK9 
To further investigate the effect of STAT3 inhibition on PCSK9 expression, HepG2 cells were 
incubated with non-toxic concentration of STAT3-inhibitor MD77 (Figure 3) (35). Incubation of 
HepG2 cells for 48h with 10-7M MD77, determined a very similar cellular responses than those 
observed with SOCS3 overexpression. In particular, incubation with MD77 induced fatty-acid 
synthase (FAS; 2.93±1.28 fold, Figure 3A), PCSK9 (2.06±0.7 fold, Figure 3B), and only marginally 
HMG-CoA reductase (1.58±0.2fold, Figure 3C), with a not statistically significant reduction of 
LDLR (-45.3±24.7%, Figure 3D). The JAK inhibitor, JAK1, significantly increased FAS (1.56±0.05 
fold, Figure 3E), PCSK9 (3.30±0.32 fold, Figure 3F) and HMG-CoA reductase (1.49±0.09 fold, 
Figure 3G), and marginally reduced the LDLR (-43.2±24.2%, Figure 3H). Consistently with the 
results with HepG2SOCS3, no effect on PCSK9 promoter activity was observed after 24h 
incubation with JAK1 (Figure 3I). Taken together, these results demonstrate that the inhibition 
of the JAK/STAT pathway induces PCSK9 in HepG2 cells.  
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FIGURE 3. Pharmacological inhibition of JAK/STAT pathway induces PCSK9 in HepG2 cells.  A-
D) HepG2 cells were seeded in MEM/10%FCS and the day after incubated with MEM containing 
10%LPDS for 24h in the presence or absence of the STAT3 inhibitor MD77 (10-7M) or E-H) JAK 
inhibitor JAK1 (10-5M). mRNA levels of FAS (A and E), PCSK9 (B and F), HMG-CoA reductase (C 
and G), and LDLR (D and H) were determined by qPCR. I) HepG2 cells were transfected with 
pGL3-PCSK9-D4 or pGL3-PCSK9-SREmut or pGL3-PCSK9-HNFmut. The day after the transfection 
the medium was replaced with MEM containing 10%LPDS with or without JAK1 (10-5M) and, 
after an additional 24h, luciferase activities were determined by Neolite reagent. Luciferase 
activities were normalized to the β-galactosidase activity of the cotransfected pRSV-
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galactosidase construct. Differences between groups were assessed by Student’s t-test (A-H) or 
1-way ANOVA (I). *p<0.05. 
SOCS3 overexpression induces de novo lipogenesis in HepG2 cells 
Several in vivo evidence demonstrated the pivotal role of SOCS3 and STAT3 on lipid metabolism 
and SREBP-1 transcriptional activity (6,7,36). To verify that a similar response also occurs in our 
experimental model, we determined the mRNA levels of SREBP-1 target genes, such as FAS and 
SCD-1 and the levels of ApoB. HepG2SOCS3 cells show higher mRNA levels of FAS (3.59±0.40 
fold, Figure 4A) as well as that of SCD-1 gene (1.92±0.12 fold, Figure 4B) and protein (3.81±0.75 
fold; Figure 4C). Together with these changes, we observed a significant increment of ApoB 
mRNA (4.08±0.41 fold, Figure 4D), and protein in the conditioned media (3.47±0.09 fold, Figure 
4E). Accumulation of intracellular TG levels (22.1±7.1μg/mg protein vs. 38.3±9.1μg/mg protein; 
Figure 4F) was seen in HepG2SOCS3, with no significant changes in total cholesterol content 
(Figure 4G). To investigate whether the observed induction of the above reported genes was 
associated to SREBP-1 activation, we evaluated the processing and expression of SREBP-1. WB 
analysis demonstrated that SOCS3 overexpression increased the active form of SREBP-1 at 68 
kDa with a significant reduction of the pro-form at 125 kDa (Figure 4H). The addition of insulin 
slightly reduced the ApoB levels in the conditioned media both in HepG2 and HepG2SOCS3 cells 
(Figure 4E). In response to TNF- we observed a significant induction of SCD-1, ApoB and FAS 
mRNA levels (2.11±0.43, 1.60±0.33 and 1.39±0.21 fold, respectively; Figure 4I-M). These 
responses were reversed in HepG2 cells transfected with siRNA STAT3 (Figure 4I-M). Taken 
together, those results indicate that the overexpression of SOCS3 induces the de novo 
lipogenesis and increased ApoB production in HepG2 cells, effects dependent by STAT3.   
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FIGURE 4. SOCS3 overexpression induces de novo lipogenesis in HepG2 cells. A, B and D) 
HepG2 and HepG2SOCS3 cells were seeded in MEM/10%FCS and the day after incubated with 
MEM supplemented with 10% LPDS for 24h. mRNA levels of FAS, SCD-1, and ApoB were 
evaluated by qPCR analysis from total RNA. C) Under the same experimental conditions, the 
SCD-1 expression was determined by WB analysis from total protein extracts. E) HepG2 and 
HepG2SOCS3 were cultured in serum free medium for 24h in the presence or absence of 10-7M 
insulin, conditioned media was than collected and ApoB concentrations determined by ELISA 
assay. F and G). Under the same experimental conditions described for panel A, the intracellular 
TG and cholesterol levels were determined in HepG2 and HepG2SOCS3 by using an enzymatic 
assay. The values were normalized for total protein content. H) WB analysis of SREBP-1. The 
45 
 
active form shows a molecular weight of 68 kDa and the respective pro-form was detected at 
125 kDa. I-M) HepG2 cells were seeded in MEM/10% FCS and the day after transfected with 
siRNA scramble and STAT3. After 48h, the medium was replaced with MEM with 10% LPDS in 
the presence or absence of 10 ng/ml TNF-. After an additional 24h, the total RNA were 
extracted and mRNA levels of SCD-1, ApoB and FAS were determined by qPCR.  Differences 
between HepG2 and HepG2SOCS3 were assessed by Student’s t-test (A-H) or 1-way ANOVA (I-
M), *p<0.05; **p<0.01; ***p<0.001.  
SOCS3 overexpression does not affect the cholesterol biosynthesis in HepG2 
A series of experiments were performed to determine the effect of SOCS3 on genes under the 
control of SREBP-2, such as HMG-CoA reductase and LDLR. HMG-CoA reductase mRNA was 
induced in HepG2SOCS3 cells (2.10±0.66 fold, Figure 5A); conversely, the LDLR mRNA levels 
were reduced in response to SOCS3 overexpression (-56%±21.6%, Figure 5B). These changes 
were not associated with significant variation of HMG-CoA reductase protein level (Figure 5C). 
The lack of significant changes of HMG-CoA reductase was also confirmed by the fact that the 
cholesterol biosynthesis was not altered in HepG2SOCS3 cells compared to HepG2 cells (Figure 
5D). 
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FIGURE 5. Cholesterol biosynthesis is not influenced by SOCS3 in HepG2 cells. A and B) HepG2 
and HepG2SOCS3 cells were seeded in MEM/10%FCS and the day after incubated with MEM 
containing 10%LPDS for 24h and HMG-CoA reductase and LDLR mRNA determined by qPCR (A 
and B, respectively). C) Under the same experimental conditions, HMG-CoA reductase 
expression was assessed by WB analysis from total protein extracts. D) HepG2 and HepG2SOCS3 
were cultured in MEM containing 10%LPDS in the presence of [14C]-Acetate. After 48 hours 
[14C]-Acetate incorporation into cellular cholesterol was evaluated. Each bar represents the 
mean±SD of triplicate dishes. Differences between HepG2 and HepG2SOCS3 were assessed by 
Student’s t-test, *p<0.05. 
SOCS3 overexpression reduces insulin-dependent activation of IRS1 and AKT 
To corroborate the pathophysiological relevance of our observations, we then investigated the 
effect of SOCS3 overexpression on insulin signaling. As shown in Figure 6A, in response to 
insulin (10-7 M), a significant induction of IRS-1 Tyr896 and Akt Ser473 phosphorylations were 
observed in HepG2. Overexpression of SOCS3 (HepG2SOCS3 cells) resulted in a reduced 
activation of both IRS-1 (Figure 6A) and AKT (Figure 6B) in response to insulin. In accordance 
with previous studies 175, ectopic expression of SOCS-3 appeared to elevate basal 
autophosphorylation, although this increase was not statistically significant. 
Moreover, STAT3 phosphorylation was induced in response to insulin in control cells (HepG2), 
while SOCS3 overexpression (HepG2SOCS3) determined an abrogation of this response (Figure 
6C). As previously reported by Costet et al 128, the incubation of HepG2 cells with insulin (10-7 
M), significantly induced both PCSK9 secretion and mRNA (Figure 7A and 7B), and the presence 
of SOCS3 further up regulated the response to insulin at the mRNA levels. However, this effect 
did not translate to a further induction of PCSK9 secretion in the cultured media, as determined 
by ELISA assay (Figure 7A). Similarly, we observed an additive effect of insulin and SOCS3 on the 
FAS and SREBP-1 mRNA levels (Figure 7C and D) with no effect on SREBP-2 and HMG-CoA 
reductase levels (Figure 7E and F), further supporting a selective activation of SREBP-1 
transcriptional activity rather than SREBP-2. 
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FIGURE 6. Effect of SOCS3 on insulin-induced IRS-1, Akt and STAT3 phosphorylation.  A-C) 
HepG2 and HepG2SOCS3 were seeded in MEM/10%FCS and starved overnight with serum free 
medium before stimulation with insulin (10-7M) for 5 and 10 min. WB analysis was then 
performed from total protein extracts by using anti-pIRS-1, anti-pAkt, anti-pSTAT3, anti-STAT3 
48 
 
and anti-α-tubulin antibodies. Densitometric analysis was than evaluated using the 
ImageLabTM software. Differences between groups were assessed by 1-way ANOVA. 
FIGURE 7. Effect of insulin on PCSK9 expression in HepG2SOCS3.  A-F) HepG2 and HepG2SOCS3 
cells were seeded in MEM/10%FCS and the day after incubated in serum free medium for 24h in 
the presence or absence of insulin (10-7M). A) At the end of the incubation, the PCSK9 levels in 
the conditioned media were evaluated by ELISA assay, and mRNA levels of PCSK9, FAS, SREBP-1, 
SREBP-2 and HMG-CoA reductase were determined by qPCR (B-F). Differences between groups 
were assessed by 1-way ANOVA. 
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DISCUSSION (I)  
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Obesity leads to the development of a low grade sub-clinical inflammation, with the release of 
pro-inflammatory proteins (adipokines and cytokines) by the adipose tissue. Pro-inflammatory 
proteins, released in the systemic circulation, interact with a variety of receptor in different 
organs. In the present work, we decided to focus our attention on the liver, where cytokines 
activate the JAK/STAT3 pathway through the interaction with cytokine receptor, expressed on 
hepatocytes surface. As a consequence of JAK/STAT3 pathway activation by pro-inflammatory 
cytokines, the protein SOCS3 is released inside the cell, with the aim of down-regulate the 
JAK/STAT3 pathway with a negative feedback mechanism. The increase in SOCS3 levels leads to 
a further release of acute phase proteins, responsible for an impaired lipid and glucose 
metabolism 29, 32-35. We know that the adipokine resistin and insulin induce both SOCS3 and 
PCSK9 expression in cultured cell lines and animal models 176-179 and that, in clinical settings, a 
positive relationships of apoB-containing lipoproteins and PCSK9 has been observed 119,130-132. 
Moreover, SOCS3 overexpression, in mice, induces SREBP-1 transcriptional activation and de 
novo lipogenesis 98,99 and PCSK9 has been shown to be transcriptionally regulated by SREBP-1 
and SREBP-2 128,129. For these reasons, in the present study, we decided to investigate the 
possible correlation between SOCS3 and PCSK9 and, in particular, to understand the effects of 
an overexpression of SOCS3 on de novo lipogenesis, insulin resistance and PCSK9 expression. 
The first novel aspect that we observed was the induction of PCSK9 in response to the pro-
inflammatory cytokine TNF-, the same factor that efficiently induces SOCS3 (Figure 1A, B, C) 
and has been implicated in chronic-inflammation associated with IR 80,91. To study the possible 
link between SOCS3 and PCSK9, we first suppressed the expression of SOCS3 by siRNA in 
HepG2. By using this approach, we demonstrated that SOCS3 is required for the TNF-α-driven 
induction of PCSK9. In addition, the silencing of STAT3 blocked the induction of SOCS3, PCSK9, 
ApoB, FAS and SCD-1 in response to TNF- (Figures 1D, E, F and Figure 4I, L). Although the effect 
of pro-inflammatory cytokines on genes regulating the de novo lipogenesis has been previously 
described 91,180, our data, candidates PCSK9 as a gene involved in lipid metabolism regulated by 
pro-inflammatory cytokine TNF-, in a SOCS3 dependent manner. We then established an 
hepatic cell line stably overexpressing SOCS3 (Figure2A, B), the endogenous inhibitor of STAT 
proteins, and consistently found to be up-regulated in the liver of genetically- and diet-induced 
obese animal 98,99. By WB analysis, we demonstrated that SOCS3 overexpression abrogated 
STAT3 phosphorylation and thus, the JAK/STAT pathway (Figure 2C). By using this cellular 
model, we observed a significant induction of both PCSK9 mRNA and protein (Figure 2D, E). The 
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involvement of both JAK and STAT proteins was then confirmed by the use of selective 
pharmacological inhibitors, JAK-I and MD77 (Figure 3). The suppression of STAT3 by siRNA 
induced PCSK9, while the opposite effect was seen after the downregulation of SOCS3 (Figure 
2I). In combination with the induction of PCSK9, we also observed increased SREBP-1 processing 
(Figure 4H) and a significant up-regulation of the key genes involved in the de novo lipogenesis, 
such as FAS and the SCD-1, together with the ApoB mRNA, ApoB secretion and intracellular TG 
(Figure 4A, B, C, D, E, F). Importantly, PCSK9 was up regulated in the liver of ob/ob mice, 
together with SOCS3 (Figure 2G, H), further supporting the link between the two genes 
observed in cultured system. The consistent and very significant induction of ApoB secretion, 
confirmed the pivotal role of SOCS3 and the related inflammatory pathway, on 
hypertriglyceridemia. In addition, our observation suggested a possible involvement of PCSK9 
on ApoB production by hepatic cells and/or by the liver of animal models previously described 
155,166,181,182. For instance, the physical interaction between PCSK9 and ApoB has been shown to 
increase ApoB production, possibly through the inhibition of intracellular ApoB degradation 166. 
Our evidence further delineate the potential link between PCSK9 and ApoB by demonstrating 
that the inhibition of the JAK/STAT pathway by SOCS3 is a common determinant of their 
increased production and secretion. Notably, recent findings suggest that PCSK9 may directly 
induce ApoB mRNA levels in enterocytes 182. It is, therefore, possible to speculate that SOCS3 
could activate a positive feedback loop by increasing the expression levels of PCSK9, which, in 
turn, determines the induction of ApoB secretion. Previous studies have established the SREBP-
dependent transcriptional activation of PCSK9. Indeed, similarly to the LDLR and other 
cholesterol-regulated genes, the proximal region of the PCSK9 promoter contains an SRE-1 
motif 128,183. In addition, two independent studies have demonstrated that insulin, by inducing 
SREBP-1c activity, induces PCSK9 both in vitro and in vivo 128,179. We confirmed this evidence at 
both mRNA and protein levels (Figure 7A, B), and the combination of SOCS3 and insulin 
determined a further induction of de novo lipogenesis genes (Figure 7C), SREBP-1 (Figure 7D), 
and PCSK9 (Figure 7B), with no additive effect on PCSK9 secretion (Figure 7A). These results are 
in agreement with previous studies showing that the inhibition of STAT proteins by SOCS3 
suppresses the transcription of SREBP-1 99,184. In our study, the transcriptional activation of 
SREBP-1 was demonstrated by the induction of key genes involved in the lipid synthesis, such as 
FAS and SCD-1 (Figure 4A, B, C), while SREBP-2 appears to be unaffected by SOCS3 since the 
cholesterol biosynthesis is not altered and an opposite regulation was observed for the HMG-
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CoA reductase and the LDLR mRNA (Figure 5). To better define the effect of SOCS3 on PCSK9 
transcription, we analyzed PCSK9 promoter activities in HepG2 and HepG2SOCS3 transiently 
expressing the PCSK9 promoter-driven luciferase reporters PCSK9-D4 172. Unexpectedly, we 
found that PCSK9-D4, the functional promoter reporter (nt 2455 to 294), was unresponsive to 
SOCS3 overexpression (Figure 2L) and incubation with JAK1 (Figure 3I), while its activity was 
induced by simvastatin in the same experimental settings (data not shown). These results 
suggest that the SOCS3 response sequences could possibly locate upstream of the promoter 
region considered. On this regard, it is important to mention that the link between JAK/STAT 
pathway and PCSK9 has been previously investigated in the same cell line by the use of the 
cytokine oncostatin M 185. Similar to our study, oncostatin M did not affect the PCSK9 promoter 
activity excluding also an epigenetic modification of the PCSK9 gene 185. Since previous studies 
have shown that PCSK9 transcription is controlled through cis regulatory elements located in 
the proximal promoter region of the PCSK9 gene where the Sp1 sites, HNF1, and SRE-1 are 
located 129,172,186. We utilized also a PCSK9-D4 containing a mutation for the HNF responsive 
element. Under this condition, we detected a significant increase of the promoter activity in 
HepG2SOCS3 cells (Figure 2L). These observations potentially related to the SREBP pathway, 
activated in response to STAT inhibition, although the overall activity was very low and 
potentially not responsible for the induction of PCSK9 mRNA levels 99. This effect was also not 
confirmed with the incubation of the JAK inhibitor (Figure 3I), most likely because of the minor 
inhibition of the pathway in comparison to the complete block after SOCS3 overexpression. 
Additional analysis are thus required to better define the effect of SOCS3 on the transcription of 
PCSK9 as well as the possible effect on mRNA stability. On this regard, it is important to point 
out that also an additional regulator of the JAK/STAT pathway, oncostatin M, was shown to 
reduce PCSK9 mRNA levels without affecting its stability185. In addition, berberine, which up-
regulates PCSK9 mRNA 187, has been shown to modulate LDLR mRNA stability by regulating the 
activity of AU-rich (AREs) elements binding proteins 172. Thus, it would be interesting to study 
the involvement of AREs proteins on PCSK9 mRNA stability. Several studies have described the 
effect of SOCS proteins on insulin signaling 70,80,188. Although the observations may differ by the 
cell type and by the time considered, the majority of the studies suggests that SOCS proteins 
control insulin action by reducing the expression of IRS proteins 70,80,188. Indeed, in our 
experimental conditions, SOCS3 overexpression reduced both IRS-1 and Akt phosphorylation in 
response to insulin (Figure 6A, B). Moreover, insulin stimulation of HepG2SOCS3 determined a 
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further induction of genes related to de novo lipogenesis (FAS and SREBP1), as well as PCSK9 
(Figure 7). Although this finding has been obtained in in vitro, it is conceivable to hypothesize a 
functional contribution of PCSK9 on the hypertriglyceridemic condition observed in type 2 
diabetes mellitus and obesity. Indeed, PCSK9 directly affects the VLDR expression at the adipose 
tissue determining the accumulation of visceral adipose tissue in mice 120. For such effect, 
PCSK9 deficient mice show adipocyte hypertrophy, enhanced in vivo fatty acid uptake, and ex 
vivo triglyceride synthesis 120. In conclusion, in the present study, we provided evidence for the 
JAK/STAT dependent expression of PCSK9 in hepatic cell line, suggesting the potential molecular 
basis of the direct relationship between PCSK9 and TG levels observed in clinical trials 119,130-132. 
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PROPROTEIN SUBTILISIN/KEXIN TYPE 9 
(PCSK9) INDUCES PRO-INFLAMMATORY 
RESPONSE IN MACROPHAGES 
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INTRODUCTION (II)  
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Role of macrophages in plaque development: 
One of the critical steps of atherosclerotic plaque development is the entering of monocytes 
inside the plaque189. These white blood cells, attracted by cytokine or growth factor produced 
within tunica intima during the inflammatory process, differentiate in macrophages and 
contribute to the increased expression of inflammatory receptors, such as toll-like receptors 
190,191, able to activate macrophages and recognize particles and molecules expressing typical 
pathogen-like pattern. In particular, the atherosclerotic process starts with the retention of 
apolipoprotein B (apoB)-containing lipoproteins, mainly the low-density lipoproteins (LDL) 
within the artery wall 192, which undergo chemical modification, in particular oxidation, and are 
recognized and capitated by scavenger receptors upon infiltrated macrophages membrane. In 
physiological conditions, this pathway  removes and destroys oxidized LDL, bacterial endotoxins 
and fragments of apoptotic cells, but if the amount of oxidized LDL is too high, cholesterol 
crystals accumulate inside macrophages cytosol, leading to foam cells formation 190, and 
promoting endothelium dysfunction and activation, with a further recruitment of white blood 
cells. Activated macrophages are responsible for the production of pro-inflammatory cytokines, 
chemokines, coagulation factors, vasoactive molecules (such as adhesion molecules), oxygen 
and nitrogen radicals and proteases. The accumulation of LDL contributes not only to the 
formation of foam cells, but also to the amplification of a chronic inflammatory state. With the 
production of many pro-inflammatory molecules, activated macrophages are responsible for 
the initiation of thrombus formation and for the destabilization of the lesion and the inhibition 
of a resistant and stable fibrous cap formation193-196. Taken together, these action lead to 
plaque rupture, a consequent thrombosis and ischemia. It appears quite clear the central role of 
macrophages in atherogenesis and several studies have clarified the existence of two different 
macrophages population, that, following in vitro criteria, can be divided into pro-inflammatory 
(M1 cells) and anti-inflammatory (M2 cells) 197. The polarization toward the M1 state is 
obtained through several stimuli, such as lipopolysaccharide (LPS) and interferon-, two of the 
Toll-like receptor (TLR) most important ligands, while the polarization toward M2 state can be 
obtain with the treatment with interleukine-4 and -13. M1 cells represent the main source of 
pro-inflammatory cytokines and have been observed in both mouse and human atherosclerotic 
plaque 197. They are responsible for the secretion of many pro-inflammatory mediators, such as 
nitric oxide synthase, tumor necrosis factor- (TNF-), interleukin-1β (IL-1β), IL-6, IL-12 and 
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proteolytic enzymes, all involved in the amplification of the inflammatory process and in the 
extracellular matrix components degradation.  
 
Figure G: Role of macrophages inflammation on the artery. Monocytes are recruited inside the 
tunica intima and differentiate in macrophages, able to bind to diverse microbial and 
endogenous particles through the toll-like receptor. Activated macrophages release pro-
inflammatory cytokines, chemokines and radicals, exacerbating inflammatory process 198. 
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Pro-inflammatory cytokines - markers of systemic inflammation: 
Pro-inflammatory cytokines are secreted from different tissues and cells in all those situation of 
infection, inflammation or trauma. Some of them are secreted locally and are responsible for 
the activation of cell surface receptor pathways that regulates inflammatory response.  
Atherosclerosis is not only a local inflammation. The development of the disease is 
accompanied with increased levels of pro-inflammatory cytokines in the bloodstream. For 
example, high levels of C-reactive protein and IL-6 can predict worse prognosis in patients 
affected by angina or myocardial infarction 11,199,200. Elevated inflammatory markers levels are 
present in patients with acute disease, but also an inactive atherosclerotic plaque can release in 
the bloodstream some markers, like C-reactive protein, erythrocyte sedimentation rate, soluble 
intracellular VCAM-1, P-selectin and fibrinogen 201,202. This observation leaded to consider those 
proteins markers of inflammatory process in the artery and predictive for cardiovascular risk 
development, also in healthy population18,203. 
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Figure H: The cytokine cascade: pro-inflammatory cytokines produced by activated 
macrophages within the plaque, reach the bloodstream, causing a further release of other 
cytokines from other tissues, like adipose tissue of patients with metabolic syndrome. In 
particular, interferon-, interleukin-1 and TNF-, produced by plaque macrophages and other 
immune cells of the plaque, induce IL-6 production, which, in turn, is responsible for the liver 
production of high amount of acute-phase reactants, like C-reactive protein, serum amyloid A 
and fibrinogen. The continuous amplification of cytokines cascade make possible clinical 
diagnosis 198.  
Tumor Necrosis Factor- (TNF-) and coronary events risk: 
TNF- is a circulating multifunctional pro-inflammatory cytokine, produced and secreted by 
endothelial cells, smooth muscle cells and macrophages within the atherosclerotic lesion204-206. 
The name of this cytokine derives from its first discovered action in the promotion of 
hemorrhagic necrosis in transplanted tumors 207, but TNF- is also involved in several 
cardiovascular processes, in particular, contributing to the development of atherosclerosis by 
inducing endothelial dysfunction. Elevated TNF- levels are observed in advanced heart failure 
208,209 and myocardial ischemia and reperfusion 210-213 and, vice-versa, coronary ischemia causes 
acute increase in TNF-, while myocardial infarction causes TNF- increase several months after 
the event 214,215. Moreover, in experimental models, TNF- is able to induce left ventricular 
dysfunction 216, pulmonary edema 217,218 and cardiomyopathy 219. In 2000, Ridker and his 
research group demonstrated that post-myocardial infarction patients, recruited in the 
Cholesterol and Recurrent Events (CARE) trial220, presented persistently elevated plasma 
concentration of TNF-, suggesting that a persistent inflammatory instability is present in stable 
patients. Moreover, those patients presenting highest TNF- levels presented also the highest 
cardiovascular risk. By decreasing the secretion of apolipoproteins, modifying sphingolipid 
content and reducing cholesterol excretion and catabolism, TNF- can interfere with 
cholesterol metabolism and can promote the formation of pro-atherogenic small dense LDL and 
oxidized LDL 221. Thus, elevated levels of TNF- can be considered as a long-term prognostic 
value among apparently stable patients. The source of this persistent TNF- elevated levels is 
still unknown, but it is possible to hypothesize that its origin derives from an increased 
infiltration of inflammatory cells in the peri-infarct zone222. From these evidences, it appears 
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quite clear that novel antiinflammatory therapies might represent a valid tool in the treatment 
of myocardial infarction20,223,224. 
Vascular inflammation and low-density lipoproteins: 
As described before, LDL-cholesterol represents the most important and validated risk factor for 
atherosclerosis. Several studies tried to clarify the possible link between cholesterol and 
inflammation, speculating different mechanisms. In 2013, Grebe and Latz, hypothesized the 
involvement of NLRP3 inflammasome, that can be able to promote the amplification of the 
immune-inflammatory response. Moreover, elevated LDL-cholesterol levels are associated with 
single nucleotide polymorphisms in the CELSR2/PSRC1/SORT1 locus and in the 
APOE/APOC1/TOMM40 locus, recently assessed as inflammatory-related phenotypes 225. There 
are also evidences of a possible link between cholesterol and proinflammatory cytokines. For 
example, is has been shown that modified LDL up regulate both IL-6, whose levels are predicting 
for future cardiovascular events 226 and correlate with carotid media-intima thickness 19 and IL-
1, the last upregulated after the activation of NLRP3 inflammasome 227,228. Among the different 
mechanisms postulated, one points toward the increase of plasma membrane cholesterol, 
through the involvement of the TLRs 229,230. 
Extrahepatic function of PCSK9: 
Despite PCSK9 is mainly expressed in the liver and exerts its principal function on hepatic LDL 
receptor, it is well known that not only the proprotein convertase is present also in other 
tissues, but it can exert diverse activities also in those tissue that are not involved in PCSK9 
secretion 108. For example, circulating hepatic PCSK9 interacts with pancreatic islets LDL 
receptor, degrading it 121,231. PCSK9 null mice present abdominal, perigonadal and perineal fat 
accumulation, suggesting that the proprotein may be involved in adipogenesis. PCSK9 is also 
expressed in the brain and, after ischemic stroke, it has a relevant impact on LDL receptor 
expression in the lesion. Recently, Zimetti et al have investigated the role of PCSK9 on 
Alzheimer’s disease, highlighting an increased PCSK9 concentration in cerebrospinal fluid of 
patients affected by the disease, even if the clinical relevance of this link needs to be more 
deepened Increased232. As said before, our research group has recently demonstrated the 
presence of PCSK9 also in the atherosclerotic lesion in vivo and it has evaluated the effect of 
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PCSK9 on macrophages LDL receptor in vitro, observing a significant degradation of the 
receptor122. 
PCSK9 and inflammation 
In the last few years, most of the research groups involved in the study of PCSK9 are moving 
their attention toward the possible involvement of this protein in inflammation, performing 
contrasting opinions and evidences. For example, in the Atheroremo IVUS Study233,234, it is 
shown a positive correlation between PCSK9 and the atherosclerotic plaque necrotic core 
fraction and, consequently, between PCSK9 and plaque inflammation. PCSK9 knock-down 
macrophages show attenuate induction of pro-inflammatory cytokines in response to oxLDL235. 
Moreover, Dwivedi and his research group demonstrated how PCSK9 deficiency confers 
protection against tissue inflammation in mice, while its overexpression exacerbates 
proinflammatory states in early sepsis conditions 236. Giunzioni et.al, showed an increased 
proinflammatory cytokine pattern in ApoE-/- transgenic mice, which express human PCSK9, 
effect that disappears in LDL receptor-/- transgenic mice 237 and Nozue et.al, demonstrated that 
PCSK9 positively correlates with oxidized LDL in patients with coronary artery disease 238. 
Exogenous overexpresson of PCSK9 in macrophages enhanced the response to LPS, increasing 
IL-1β and TNF- expression and decreasing anti-inflammatory markers such as Arg1 and IL-10, 
while PCSK9 null mice show blunted systemic response to LPS treatment239. Lastly, LDL receptor 
increased expression is associated with protection from severe sepsis240. After the authorization 
of the use of monoclonal antibodies anti PCSK9 in therapy, the first evidences of their possible 
effect on inflammation are coming out. In particular, by lowering PCSK9 and, consequently, 
lowering circulating LDL cholesterol, monoclonal antibodies showed a significant reduction in 
the pro-inflammatory monocytes phenotype, typical of patients affected by familial 
hypercholesterolemia241. In contrast, in patients with established coronary heart disease or in 
patients presenting high cardiovascular risk, the use of RG7652 (one of those monoclonal 
antibodies) did not affect neither systemic circulating pro-inflammatory cytokines, nor C-
reactive protein242. In the first part of this work, we demonstrated that PCSK9 present a strong 
correlation with the proinflammatory JAK/STAT243, so we decided to deepen this part of our 
research. 
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AIM OF THE STUDY (II) 
 
From the previous part of this work, we know that PCSK9 hepatic expression is regulated by 
pro-inflammatory cytokines activation of the JAK/STAT pathway. The second part of the present 
study aimed to test the hypothesis of a direct pro-inflammatory effect of PCSK9 on THP-1 
derived macrophages, human macrophages and bone marrow mouse macrophages. 
Moreover, it has been observed that PCSK9 activities are dependent by its interaction with LDL 
receptor. We wanted to understand if the possible pro-inflammatory activity of PCSK9 was LDL 
receptor-dependent too, or if other receptors may be involved. 
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MATERIAL AND METHODS (II) 
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Reagents and antibodies: 
RPMI media was obtained by Sigma, penicillin, streptomycin, nonessential amino acid solution, 
FCS, disposable culture flasks and petri dishes were from Euroclone. Molecular weight protein 
standards, SDS, TEMED, ammonium persulfate, glycine, and acrylamide solution (30%T, 2.6%C) 
were from BIO-RAD Laboratories. BCA assay for determination of protein concentrations was 
purchased from Thermo Scientific. Recombinant Tumor Necrosis Factor-α (TNF-α) was 
purchased from Sigma. Recombinant PCSK9 was obtained by Vinci Biochem. The JAK inhibitor 
JAK1 was purchased from Millipore and fatostatin hydrobromide from Sigma. 
Cell culture: 
THP1-derived macrophages: THP-1 monocyte cells were cultured in RPMI media supplemented 
with penicillin (10,000 U/mL), streptomycin (10 mg/mL), nonessential amino acid, 10% Fetal Calf 
Serum (FCS) and β-mercaptoethanol 0.05mM. In order to obtain THP-1 macrophages derived 
cells, THP-1 monocytes were seeded in appropriate multiwell plate and additioned with PMA 
(3.2 x 10-7M) for 72h.  
Preparation of Human Macrophages: Human monocytes were obtained from healthy donors 
from Centro Cardiologico Monzino who gave their informed consent to participate in the study. 
Blood sampling - Venous blood samples were obtained by venipuncture of the antecubital vein 
with a 19G needle without venous stasis. After discarding the first 4 ml, blood was drawn into 4 
ACD-containing vacutainers (Becton Dickinson, CA, USA) for monocyte isolation and into one Z-
vacutainer (Becton Dickinson, Ca, USA) for serum preparation. Haemocrome was assessed by 
Sysmex XS-1000i hematologic analyzer (Kobe, Japan). Serum preparation - Serum was obtained 
by incubating blood at 37°C for 1 hour followed by centrifugation at 1700 g, 10 minutes at 4°C, 
transferred, under sterile conditions, into a new tube and stored at 4°C until use. Monocytes 
isolation - Immediately after withdrawal, ACD-anticoagulated blood was centrifuged at 100g, 10 
minutes at room temperature with no brake. The platelet rich-plasma was completely removed 
and the remaining blood was mixed with RPMI (Lonza, 1640, Swiss) containing 0,1% L-glutamine 
(Thermo Fisher, USA), 0.5% Pen-strep (Thermo Fisher, USA), 20% Fetal Calf Serum (FCS, 
Euroclone, Italy) and 0.38% sodium citrate (Sigma, Germany) to restore the initial volume of 
blood in the tubes. Mononuclear cells were isolated by Ficoll-Paque Plus (GE Healthcare, vWR 
Int., Milan, Italy) density centrifugation at 600g, 20 minutes at room temperature with no brake. 
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Cells were washed with PBS (Thermo Fisher, USA) containing 0,1% glucose (Sigma, Germany), 
0,5% BSA (Sigma, Germany) and 5 mM EDTA and centrifuged at 830g for 10 minutes at 4°C with 
brake. Cells were further washed twice in PBS without EDTA and centrifuged at 350g for 10 
minutes at 4°C with brake. Mononuclear cells resuspended in RPMI supplemented with 10% 
autologous serum, 0,1% L-glutamine and 0.5% Pen-strep were then plated (100.000 
monocytes/100 µl) in a 48 Well Cell Culture Plate (Corning Incorporated, USA) and incubated at 
37°C. After 2 hours, cells were washed 3 times with PBS in order to remove non-adherent 
lymphocytes; adherent monocytes were then cultured in the same medium over 7 days at 37°C 
(5% CO2). Medium was not replaced throughout the culture period. 
Murine bone marrow macrophages (BMM) isolation: 
Bone marrow macrophages were collected from the femur and tibia of C57BL/6 or LDLR-/- 
mice. All experiments were conducted in conformity with the Public Health Service Policy on the 
Humane Care and Use of Laboratory Animals and performed with the approval of the Ethical 
Committee for Animal Experiments of the University of Parma. After isolation, cells were 
seeded in 24 well plates in high glucose DMEM containing 30% L-929 cells conditioned medium 
and 10% FBS and maintained at 37°C, 5% CO2. After 4 days, non-adherent cells were removed 
and fresh medium was added. After additional 3 days, cells were differentiated and treated 
according to the protocol.  
Generation of human PCSK9 expression construct and retroviral infection in HepG2 cells: 
The retroviral expression plasmid encoding PCSK9-FLAG tag was constructed using the pBM-
IRES-PURO plasmid. Human PCSK9-FLAG tag cDNA was kindly provided by Prof. P. Tarugi 
(University of Modena) and subcloned into retroviral expression plasmid by blunt-end ligation. 
Retroviral infections of HepG2 were performed as previously described (Material and methods 
I). A polyclonal population of HepG2 control and PCSK9 overexpressing cells have been then 
selected with 10µg/ml of puromycin.  
HepG2PCSK9 and THP-1 co-culture: HepG2 and HepG2PCSK9 were cultured together with THP-1 
derived macrophages in a transmembrane system (Transwell, Corning, Lowell, MA, USA) using 
polycarbonate membrane with 0.4 μm pores. HepG2 and HepG2PCSK9 cells were seeded in 6-
well plates at a density of 6x105 cells/well in MEM with 10%FCS. After 3 days, HepG2 medium 
was discarded and THP-1 cells, suspended in fresh medium containing 3.2 x 10-7M of PMA, in 
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order to differentiate them in macrophages, were added in the transmembrane system to each 
well seeded with HepG2 and HepG2PCSK9 cells, at a density of 2x105 cells/well.  
RNA preparation and quantitative real time PCR (qRT-PCR) assay: 
THP-1 derived macrophages and human macrophages: THP1-derived and human macrophages 
(differentiated respectively from THP-1 monocytes and human monocytes as previously 
described), were seeded in 48 well plates (500.000 cells/well) and treated for 24h with PCSK9 
-α 10ng/ml as positive control. Total mRNA was extracted 
from the cells, after 24h of treatments, using iScript Sample Preparation Buffer (BIO-RAD 
laboratories, Hercules, CA, USA), according to manufacturer’s instructions. Reverse 
transcription-polymerase first-strand cDNA synthesis was performed by using the iScript cDNA 
synthesis Kit (BIO-RAD laboratories, Hercules, CA, USA) and for Real time PCR were used the Kit 
Thermo Sybr Green/ROX qPCR Master Mix (Carlo Erba Reagents S.r.l. Cornaredo, Milan, Italy) 
and specific primers of the genes of interest (described below). 
Murine bone marrow derived macrophages: The analyses were performed with the ABI Prism® 
7000 Sequence Detection System (Applied Biosystems). PCR cycling conditions were as follows: 
94°C for 3min, 40 cycles at 94°C for 15s, and 60°C for 1min. Data were expressed as Ct values 
and used for the relative quantification of targets with the ΔΔCt calculation. We evaluated gene 
expression of: 
Table 2. Primer sequence utilized for the qPCR analysis. 
Primer Forward Reverse 
18S 5’-CGGCTACCACATCCACGGAA-3’ 5’-CCTGTATTGTTATTTTTCGTCACTACC-3’ 
   
Human   
IL-6 5-’GGTACATCCTCGACGGCATCT-3’ 5’-GTGCCTCTTTGCTGCTTTCAC 
IL-1β 5’-ATGCACCTGTACGATCACTG-3’ 5’-ACAAAGGACATGGAGAACACC-3’ 
TNF- 5’-ACTTTGGAGTGATCGGCC-3’ 5’-GCTTGAGGGTTTGCTACAAC-3’ 
CXCL-2 5’-CGCCCATGGTTAAGAAAATCA-3’ 5’-CCTTCTGGTCAGTTGGATTTGC-3’ 
MCP1 5’-CGCCTCCAGCATGAAAGTCT-3’ 5’-GGAATGAAGGTGGCTGCTATG-3’ 
LDLR 5’-GTGTCACAGCGCCG-3’ 5’-CGCACTCTTTGATG-3’ 
CAP1 5’-ACTGGCCTGGAGCAAAACG-3’ 5’-CGGCAGAGGGTCCAGATG-3’ 
   
Mouse   
TNF- 5’-CCCTCACACTCAGATCATCTTCT-3’ 5’-GCTACGACGTGGGCTACAG-3’ 
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ELISA assay: 
THP-1 derived macrophages and human macrophages (differentiated respectively from THP-1 
monocytes and human monocytes as previously described) were seeded in 6 well plates 
(3.000.000 cells/well) in RPMI 10%FCS and then treated with for 24h with PCSK9 0.25, 0.5, 1 and 
2.5 µg/ml and TNF-α 10ng/ml as positive control. Conditioned media from treated cells was 
collected and used for the protein quantification of IL-6 and TNF-α, through ELISA kit (Human IL-
6 Quantikine ELISA Kit and Human TNF-alpha Quantikine ELISA Kit, R&D Systems respectively). 
Western Blot analysis: 
THP-1 macrophages and human macrophages (differentiated respectively from THP-1 
monocytes and human monocytes as previously described) were seeded in 6well plate, in a 
concentration of 3.000.000 cells/well. Cells were treated for 24h with PCSK9 0.25, 0.5, 1 and 2.5 
g/ml and TNF-α 10ng/ml as positive control and, the day after, total cytosolic protein extracts 
were obtained by collecting cells in 200μl of Mammalian Protein Extraction Reagents (Thermo 
Fisher Scientific, MA, USA) containing a cocktail of protease and phosphatase inhibitors (Roche 
Diagnostics S.p.A., Monza, Italy). Molecular mass marker (Novex® Sharp Protein Standard, 
InvitrogenTM; Life Technologies Europe BV, Milan, Italy) and proteins were separated through 
10-12% SDS-PAGE gel. Proteins were then transferred to a nitrocellulose membrane and 
blocked with albumin buffer containing 0.05% of TWEEN. Incubation with primary antibodies 
occurred overnight at 4°C with the following antibodies: LDL Receptor rabbit Polyclonal 
Antibody 1:200 (Cayman Chemical, 1180 East Ellsworth RD Ann Arbor, MI 48108 – USA), and -
tubulin (Sigma-Aldrich) 1:5000. Membrane was incubated with anti-mouse and anti-rabbit 
peroxidase-conjugated secondary antibodies (1:5000) (Jackson ImmunoResearch Lab; 
Cambridgeshire, UK). Immunoreactive bands were detected by acquiring images with Odyssey®, 
LI-COR Biosciences, Carlo Erba, Milan, Italy. Densitometric readings were evaluated using the 
Image Studio Software. Results were normalized with -tubulin. 
IL-6 5’-GAGGATACCACTCCCAACAGACC-3’ 5’-AAGTGCATCATCGTTGTTCATACA-3’ 
IL-1β 5’-CAACCAACAAGTGATATTCTCCATG-3’ 5’-GATCCACACTCTCCAGCTGCA-3’ 
CXCL-2 5’-CCAAGGGTTGACTTCAAGAAC-3’ 5’-AGCGAGGCACATCAGGTACG-3’ 
MCP-1 5’-ACCACAGTCCATGCCATCAC-3’ 5’-TTGAGGTGGTTGTGGAAAAG-3’ 
LDLR 5’-GTGTGACCGTGAACATGACTGC-3’ 5’-CACTCCCCACTGTGACACTTGA-3’ 
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Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde at room temperature for 10 min, permeabilized in 
0.1% Triton X-100 in PBS for 5 min, and incubated for 1 h with 1% bovine serum albumin (BSA). 
Cells were then incubated with primary antibody anti NF-κB p65 (Rabbit polyclona GeneTex) for 
1 h at room temperature, followed by three washes with PBS and subsequent incubation with 
Alexafluor®-568 anti-rabbit antibody. Cells were then washed four times with PBS, incubated 
with DAPI solution for 5 min, mount and coversliped with Vectashield. Immunostaining of cells 
was analyzed by fluorescent confocal microscope (Zeiss LSM 800).  
Subjects 
Study participants were patients enrolled in the Brisighella Heart Study. All the involved subjects 
have signed an informed consent form. The Brisighella Heart Study protocol and its substudies 
have been evaluated and approved by the Ethical Board of the S. Orsola-Malpighi University 
Hospital (Bologna, Italy). We selected a sample of overall healthy adult subjects (M: 533, F: 
537), after exclusion of active smokers, those subjects affected by chronic inflammatory 
disorders (including atopic diseases) and subjects chronically assuming non-steroidal 
antinflammatory drugs, systemic corticosteroids, or immunosuppressants 16. A Pearson's 
bivariate correlation followed by a multiple linear regression have been carried out to evaluate 
the eventual relationship between TNF-α and PCSK9 plasma levels in humans. 
Analysis of data 
Statistical analysis. Statistical analysis was performed using the Prism statistical analysis package 
version 5.01 (GraphPad Software). Data are given as mean ± SD of three independent 
experiments. When possible, p-values were determined by Student’s t-test. Otherwise, 
differences between treatment groups were evaluated by 1-way ANOVA. A probability value of 
p<0.05 was considered statistically significant. 
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RESULTS (II) 
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PCSK9 exerts a pro-inflammatory activity on THP-1 derived macrophages: 
To test the hypothesis that PCSK9 could have a pro-inflammatory effect on macrophages, we 
performed a series of experiments with macrophages derived from human monocyte cell line 
THP-1 differentiated with PMA, incubated with increasing concentrations of human 
recombinant PCSK9. The incubation for 24h induced the mRNA levels of proinflammatory 
cytokines, markers of M1 phenotype, IL-1β, IL-6 and TNF-α (Figure 1A, B and C). In particular, 
the effect of hPCSK9 on IL-1β appears to be more concentration-dependent, with a significant 
induction from 250 ng/ml up to 2.5 µg/ml (Figure 1A). The mRNA levels of TNF-α also increased 
in a concentration-dependent manner, although a significant difference was observed between 
1 and 2.5 µg/ml (5.1±1.6 fold vs 67.4±25.9 fold, respectively) (Figure 1B). Similar effect was also 
observed for the mRNA of IL-6, where hPCSK9 strongly induced its levels (36.4±19.3Fold) 
exclusively at 2.5 µg/ml with no effect from 250 ng/ml and 1 µg/ml (Figure 1C). The 
determination of mRNA levels of monocyte chemokines, such as MCP-1 and CXCL-2 also 
revealed a positive effect of hPCSK9 (Figure 1 D and E), with a concentration dependent 
response for MCP-1 (similar to IL1-β) and a strong induction at 2.5 µg/ml for CXCL-2 (similar to 
TNF-α). THP1 macrophages were also incubated with TNF-α (10 ng/ml) as positive control. 
Importantly, the effect of 250 ng/ml hPCSK9, thus within its physiological serum concentrations 
(median 270 ng/mL, ranging from 91 to 804 ng/mL234), exerted a similar pro-inflammatory 
effect than TNF-α. 
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Figure 1: Increased gene expression of different proinflammatory cytokines in THP-1 derived 
macrophages, in response to hPCSK9. THP-1 monocytes were seeded in 48 well plate (500.000 
cells/well) in RPMI 10%FCS and differentiated in macrophages with PMA 3.2 x10-7M for 72h. 
THP-1 derived macrophages were then incubated for 24h with TNF- 10ng/ml (as positive 
control) and different concentration of recombinant hPCSK9 (0.25, 0.5, 1 and 2.5 g/ml). At the 
end of the incubation, total RNA was extracted and (A) IL-1β, (B) IL-6, (C) TNF-, (D) CXCL-2 and 
(E) MCP-1 gene expression was evaluated through qRT-PCR. Differences between basal and 
treated samples were assessed by Student’s t-test: *p<0.05; **p<0.01; ***p<0.001. 
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The equimolar concentration of albumin did not induce pro-inflammatory response on THP-1 
macrophages: 
In order to assess if the results obtained were due to the incubation of THP-1 derived 
macrophages with an high amount of protein, we treated cells with the equimolar 
concentration of albumin (BSA), following the same experimental condition used for the 
incubation with PCSK9. We did not observe any pro-inflammatory response in cells after 24h of 
incubation. 
 
Figure 2: The treatment with an equimolar concentration of BSA does not induce pro-
inflammatory response in THP-1 derived macrophages. THP-1 monocytes were seeded in 48 
well plate (500.000 cells/well) in RPMI 10%FCS and differentiated in macrophages with PMA 3.2 
x10-7M for 72h. THP-1 derived macrophages were then incubated for 24h with two 
concentration of BSA (1 and 2.5 g/ml). At the end of the incubation, total RNA was extracted 
and TNF- gene expression was evaluated through qRT-PCR. Differences between basal and 
treated samples were assessed by Student’s t-test: *p<0.05; **p<0.01; ***p<0.001. 
The incubation with human recombinant PCSK9 activates NF-κB transcription factor 
Since transcription of the majority of proinflammatory cytokines are under the control of 
nuclear factor-κB (NF-κB) transcription factor, we investigated the effect of PCSK9 on the 
nuclear localization of p65 subunit in THP-1 derived macrophages. As expected, the incubation 
with TNF-α induces a marked response of NF-κB activation with positive nuclear staining of p65 
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cells NF-κB in approximately 30% of the cells, while no nuclear staining was observed under 
basal condition. Interestingly, the incubation with 2.5µg/ml of PCSK9 induced a significant NF-κB 
activation, with 16% of the cells with positive nuclear staining for p65 (Figure 3). 
 
Figure 3: PCSK9 increases NF-κB nuclear activation. THP-1 macrophages were incubated with 
TNF-α 10ng/ml (as positive control) and recombinant hPCSK9 (2.5 μg/ml). After 24h cells were 
fixed and immunostaining performed for NF-κB p65 (blue: nuclei; green: p65 NF-κB). Arrows 
indicate cells with positive nuclear staining of p65.  
74 
 
PCSK9 exerts a pro-inflammatory activity on human macrophages from healthy volunteers: 
To extend our observation, we performed the same analysis on human macrophages derived 
from plasma of healthy volunteers. A concentration-dependent effect of hPCSK9 on mRNA 
levels of IL-1β, IL-6 and TNF-α was observed, with a significant induction at 1 µg/ml and 2.5 
µg/ml for all genes. As observed with THP-1, hPCSK9 induced IL-1β also at 250 ng/ml. A 
significant increase of MCP1 and CXCL2 mRNA levels were observed after incubation with 2.5 
µg/ml of hPCSK9 (Figure 4).  
To further validate our observation, we determined, by ELISA assay, the effect of hPCSK9 on IL1-
β and IL-6 released by human macrophage in the cultured media. As shown in Figure 5, 24h 
incubation with 2.5 µg/ml hPCSK9 significantly increased both IL-6 and TNF-α concentration 
(3.6±1.3 fold and 4.5±0.2 fold, respectively).  
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Figure 4: Increased gene expression of different proinflammatory cytokines in human 
macrophages, in response to hPCSK9. Human monocytes were seeded in 48 well plate 
(500.000 cells/well) in RPMI additioned with 10% of the volunteer autologous serum for 1 week, 
in order to differentiate them in macrophages. After incubation for 24h with TNF- 10ng/ml (as 
positive control) and different concentrations of recombinant hPCSK9 (0.25, 0.5, 1 and 2.5 
g/ml), quantitative (A) IL-1β, (B) IL-6, (C) TNF-, (D) CXCL-2 and (E) MCP-1 gene expression 
analysis were performed from total RNA extracted from cells. Differences between basal and 
treated samples were assessed by Student’s t-test: *p<0.05; **p<0.01; ***p<0.001. 
76 
 
 
Figure 5: Increased IL-6 and TNF- protein expression in human macrophages media, in 
response to hPCSK9. Human monocytes were seeded in 6 well plates in RPMI containing 10% of 
the volunteer autologous serum and incubated for 1 week in order to differentiate them in 
human macrophages. Macrophages were then incubated for 24h with TNF- 10ng/ml (as 
positive control) and different concentrations of recombinant hPCSK9 (0.25, 0.5, 1 and 2.5 
g/ml). IL-6 and TNF- protein expression was then assessed through ELISA analysis on 
collected media. Results were expressed as pg of protein for ml of media. Differences between 
basal and treated samples were assessed by Student’s t-test: *p<0.05; **p<0.01; ***p<0.001. 
 
Taken together, recombinant hPCSK9 induced a pro-inflammatory response in both THP1 and 
human macrophages, showing a robust induction of mRNA of IL-1β, IL-6, TNF-α, MCP1, CXCL2, 
and an increased IL-1β and TNF-α released from human macrophages.  
PCSK9 levels positively correlate with TNF- plasma concentration in Brisighella Heart Study 
population 
To further corroborate our results, we investigated a possible correlation between PCSK9 and 
TNF-α plasma levels from a selected overall healthy adult subjects (males 533, females 537) 
enrolled in the Brisighella Heart Study244. The main characteristics of the selected subjects are 
resumed in Table 3. The Pearson's bivariate correlation between TNF-α and PCSK9 showed a 
correlation coefficient of 0.388 with a p<0.001 (Figure 6). After adjustment for age, gender, and 
BMI, in the multiple linear analysis, TNF-α and PCSK9 plasma levels were significantly related 
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(B= 8.73, 95%CI 7.54÷9.93, p<0.001 (Figure 6). This evidence further support a relationship 
between chronic inflammation and PCSK9 levels. 
 
Figure 6: Relationship between TNF-α and PCSK9 serum levels. Results were determined by 
ELISA assay from human samples.  
 Mean ± SD 
AGE 57.66 ± 11.77 
BMI 23.33 ± 3.46 
SBP 130.02 ± 11.37 
DBP 67.78 ± 7.12 
TC 218.12 ± 19.38 
TG 118.29 ± 69.35 
HDL-C 51.97 ± 5.54 
LDL-C 141.58 ± 18.31 
FPG 93.24 ± 5.61 
SUA 5.215 ± 1.29 
GOT 23.17 ± 7.59 
GPT 24.13 ± 9.32 
gGT 25.67 ± 13.47 
Creatinine 1.03 ± 0.19 
eGFR (CKD-EPI) 81.30 ± 15.41 
PCSK9 (ng/ml) 286.25 ± 81.14 
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TNF alpha (pg/ml) 6.69 ± 3.60 
 
Table 3: main characteristics of the selected subjects of the Brisighella Heart Study 
PCSK9 secreted from HepG2PCSK9 induces a pro-inflammatory response in THP-1 derived 
macrophages 
To exclude a possible effect of endotoxins present in recombinant hPCSK9 and to further 
establish the pro-inflammatory effect of PCSK9, we performed co-cultured experiments of THP-
1 macrophages and HepG2 control or overexpressing PCSK9. HepG2 were transduced with 
pBM-IRES-PURO retrovirus encoding control vector (PURO) or human PCSK9. After puromycin 
selection, we measured the amount of PCSK9 released in the cultured media by ELISA assay. 
While control HepG2 cells released 1.7 ng/ml of PCSK9, the HepG2PCSK9 reached 
approximately 100 ng/ml (90±0.1 ng/ml) (Figure 7A). The co-culture with THP1 macrophage 
showed that the exposure to conditioned media from HepG2PCSK9 significantly induced the pro-
inflammatory genes TNF-α and IL-1β, by 2.4±0.5 fold and 8.6±1.8 fold, respectively, as 
compared to HepG2 (Figure 6B and C).  
 
Figure 7: PCSK9 released from HepG2 increased TNF-α and IL-1β gene expression in THP-1 
derived macrophages. THP-1 macrophages were co-cultured with HepG2 or HepG2PCSK9 
seeded on top of the transwell system. After 24h, total RNA was extracted from THP-1 
macrophages and TNF-α and IL-1β gene expression was evaluated by qRT-PCR. Differences were 
assessed by Student’s t-test (A) or one-way ANOVA (B, C), *p<0.05; **p<0.01; ***p<0.001. 
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PCSK9 pro-inflammatory effect is mainly, but not entirely, due to LDL receptor interaction 
Since the main molecular target of PCSK9 is the LDL receptor, we performed the same analysis 
on bone marrow macrophages (BMM) isolated from C57BL/6 and LDLR-/- mice. The incubation 
of BMM macrophage LDLR+/+ with increasing concentrations of hPCSK9 determined a significant 
induction of the LDL receptor mRNA (Figure 8A), and a downregulation of LDL receptor (-33% at 
2.5 µg/ml), as assessed by western blot analysis (Figure 8B). Under the same experimental 
conditions, BMM LDLR+/+ respond to 2.5 µg/ml hPCSK9 by increasing the expression of TNF-α 
(31.1±6.1 fold), while no significant effect was observed at lowest PCSK9 concentrations (Figure 
8C). Interestingly, the BMM LDLR-/- showed only a marginal increase of TNF- expression 
(4.3±1.6 fold), which is significantly lower than that observed in BMM LDLR+/+. The different 
response to PCSK9 is further validated by the fact that both macrophage types respond at 
similar extent to TNF-α (5.7±1.5 vs 4.9±0.3 fold for BMM LDLR+/+ and BMM LDLR-/-, respectively) 
(Figure 8C). Taken together, the present results suggest that the pro-inflammatory response of 
PCSK9 on macrophages is mainly, but not exclusively, dependent by the presence of the LDL 
receptor. 
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Figure 8: Lower increase of TNF- gene expression in murine LDLR-/- BMM after treatment 
with recombinant hPCSK9. Both WT and LDLR-/- murine BMM were incubated for 24h with 
TNF- 10ng/ml (as positive control) and different concentrations of recombinant hPCSK9 (0.25, 
0.5, 1 and 2.5 g/ml). Total RNA and total proteins were extracted and (A) TNF- gene 
expression was evaluated. (B) The absence of LDLR in LDLR-/- murine bone marrow 
macrophages was confirmed by qt-PCR from total RNA and (C) by western blot analysis from 
total protein extracts. Differences between basal and treated samples (*) and between BMM 
LDLR+/+ and BMM LDLR-/- (†) were assessed by Student’s t-test (A) or one-way ANOVA (B, C), 
*p<0.05; **p<0.01; ***p<0.001. †p<0.05; ††p<0.01; †††p<0.001. 
The pharmacological inhibition of JAK/STAT pathway and SREBP totally abrogates pro-
inflammatory response after the treatment with PCSK9 in THP-1 macrophages 
Interestingly, the pharmacological inhibition of Janus Kinase (JAK)/Signal Transducer and 
Activator of Transcription (STAT) signaling, by a JAK inhibitor, and of SREBP pathway, by 
fatostatin, completely prevented the induction of the TNF-α mRNA by PCSK9.  
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Figure 9: The pharmacological inhibition of both JAK/STAT and SREBP pathways prevents the 
pro-inflammatory response to PCSK9 treatment in THP-1 macrophages. THP-1 monocytes 
were seeded in 48 well plate (500.000 cells/well) in RPMI 10%FCS and differentiated in 
macrophages with PMA 3.2 x10-7M for 72h. THP-1 derived macrophages were then incubated 
for 24h with TNF- 10ng/ml (as positive control), PCSK9 2.5g/ml, the pharmacological inhibitor 
of the JAK/STAT pathway, JAKi, at a concentration of 10-5M and the pharmacological inhibitor of 
SREBP, fatostatin, at a concentration of 100M. We incubated cells also with JAKi 10-5M + 
PCSK9 2.5g/ml and fatostatin 100M + PCSK9 2.5g/ml combinations. At the end of the 
incubation, total RNA was extracted and TNF- gene expression was evaluated through qRT-
PCR. Differences between basal and treatments (*) and between PCSK9 2.5g/ml treatment 
and JAKi 10-5M + PCSK9 2.5g/ml and fatostatin 100M + PCSK9 2.5g/ml treatments (†) were 
assessed by one-way ANOVA, *p<0.05; **p<0.01; ***p<0.001. †p<0.05; ††p<0.01; †††p<0.001.  
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DISCUSSION (II) 
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In the present study, we demonstrated that human recombinant PCSK9 drives an inflammatory 
response on macrophages by inducing the pro-inflammatory cytokines TNF-α, IL-1 and IL-6, and 
the chemokines MCP-1 and CXCL2. This effect was observed in THP-1 (Figure 1), human primary 
(Figure 4), and bone marrow derived macrophages (Figure 8B). In addition, the inflammatory 
response was observed when THP-1 macrophages were co-cultured with HepG2 cells 
overexpressing PCSK9 (Figure 7). This data excludes the possibility that endotoxin 
contamination of human recombinant PCSK9 can be responsible for the proinflammatory effect 
observed. Finally, we found a positive correlation between plasma levels of PCSK9 and TNF-α, in 
a population of overall healthy subjects 245 (Figure 6 – Brisighella Hearth Study), an observation 
that further support the role of PCSK9 on inflammation. Macrophages present in the 
atherosclerotic plaque are derived, mainly but not exclusively, from circulating monocytes that 
differentiated into macrophages within the arterial wall 246. The main function of macrophages 
is to scavenge lipoprotein particles, and eventually to become foam cells 247, which then 
contribute to a local release of inflammatory molecules and factors that further promote 
lipoprotein retention and extracellular matrix degradation 248. Macrophages are very 
heterogeneous cells that can polarized to different phenotypes in response to the 
environmental cues encountered 249. Local cytokines, as well as oxidized LDL, have a very potent 
effect on macrophage polarization and our data show that PCSK9 is also capable to influence 
the pro-inflammatory status of macrophages 250. The discovery that PCSK9 is present in the 
atherosclerotic plaque argues a possible local effect on SMCs, macrophages and endothelial 
cells 122. PCSK9 can reach the plaque from the bloodstream, as it binds to lipoproteins 251, or 
been synthesized within the arterial wall from SMCs 122,252. Both sources can be theoretically 
possible since both protein and mRNA PCSK9 have been detected in the human atherosclerotic 
plaques 122,252. Although the intraplaque concentration of PCSK9 is not known, it is important to 
underlying that we observed a pro-inflammatory effect on macrophages at relatively low 
concentrations, starting from 250 ng/ml, thus even below the mean plasma levels found in 
observational studies 245. The translation of our findings to experimental atherosclerosis and 
human pathology still needs to be determined. However, alirocumab, a monoclonal antibody 
anti PCSK9, has shown to influence the atherosclerotic plaque development towards a more 
stable characteristic with reduced macrophage content and higher deposition of extracellular 
matrix 253. In addition, the treatment with 14 monoclonal antibodies anti PCSK9 reduces the 
CCR2 expression and the migratory capacity of circulating monocytes in familial 
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hypercholesterolaemia (FH) patients. This effect seems to be due to a reduction of both LDL-C 
circulating levels and intracellular lipid accumulation. This evidence suggest a possible 
association between LDL-C lowering and anti-inflammatory effect on circulating monocytes 241. 
In addition, the ATHEROREMO-IVUS study demonstrated a linear relationship between fraction 
and amount of necrotic core tissue in coronary atherosclerosis and PCSK9 plasma levels, 
independently of serum LDL cholesterol levels 234. In the attempt to define the molecular 
mechanism of the pro-inflammatory effect of PCSK9, we have utilized macrophages derived 
from LDL receptor null mice. From these analysis, we observed that the presence of the LDL 
receptor is required for the effect of PCSK9, although a significant induction of TNF-α was still 
present in BMM LDLR-/- (Figure 8). Thus, additional receptors targeted by PCSK9, such as CD36 
254, VLDLR, LRP-1 255 or ApoER2 256, could participate in the pro-inflammatory response. Our 
data are in agreement with in vitro 237 and in vivo experimental settings 257. By using chemical 
inhibitors, we also demonstrated that the proinflammatory effect of PCSK9 is dependent by the 
activation of JAK and SREBP pathways (Figure 9). Although the regulation of the intracellular 
molecular pathways by PCSK9 requires further investigations, it is relevant to note that THP-1 
derived macrophages showed a nuclear localization of p65 NF-κB proinflammatory transcription 
factor, although at lower extent than the TNF-α (Figure 3). This evidence further support a prof-
inflammatory function of PCSK9 as potential cytokine. Native LDL, a natural LDL receptor ligand, 
has recently shown to promote the differentiation of monocytes to macrophages 258. In 
particular, LDL facilitated the M1 polarization, blocked the ability of monocytes to polarize into 
M2 macrophages, and enhanced the inflammatory M1 response 258. From this evidence, it is 
conceivable to hypothesize that LDL particles and PCSK9 activate similar intracellular signaling 
pathways by interacting with the LDL receptor, which induce a pro-inflammatory effect on 
macrophages. By using a bone marrow transplantation model, Fazio et al, have investigated the 
effect of specific PCSK9 overexpression in macrophages on experimental atherosclerosis 237. 
Despite no differences on lipid profile, the lesions of mice with macrophages expressing the 
PCSK9 transgene, showed LDL receptor-dependent increase of pro-inflammatory monocytes 237. 
In line with our finding, the expression of PCSK9 increased the presence of CD11b- and Ly6Chi-
positive cells in spleens of 15 apoE−/− mice 237. Lastly, the presence of PCSK9 significantly 
improves the pro-inflammatory response to lipopolysaccharide (LPS) 237. Thus, our findings are 
in agreement with this study and further extend the pro-inflammatory effect of PCSK9 in the 
absence of a co-stimulus, such as LPS. On this matter, it is important to mention that 
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lipoproteins and their receptors play a key role during sepsis as they favor the hepatic clearance 
of endotoxins, such as LPS. Indeed, PCSK9 null mice show higher hepatic LDL receptor 
expression and improved clearance of bacterial endotoxin via the LDLR pathway, and a higher 
resistance to LPS-induced septic shock 239. Together with pro-inflammatory cytokines, PCSK9 
significantly induced two chemokines relevant for monocyte recruitment in the atherosclerotic 
plaque, such as MCP-1 259 and CXCL2 260 (Figure 1D, E and Figure 2D, E). From this in vitro 
observation, it is tempting to speculate that PCSK9 could promote a local inflammatory 
response by reinforcing the recruitment of circulating monocytes and neutrophils in the 
atherosclerotic plaque. Nevertheless, additional and more specific experiments needs to be 
performed in order to demonstrate this action. In the attempt to translate our findings to a 
clinical setting, we performed a correlation analysis between the plasma levels of PCSK9 and 
TNF-α in a population of healthy subjects recruited in the Brisighella Heart Study 244. For the 
analysis, we excluded those subjects affected by chronic inflammatory disorders, and those 
chronically assuming non-steroidal antinflammatory drugs, systemic corticosteroids, or 
immunosuppressants. Interestingly, a positive association between the two factors was found, 
supporting the possibility that either TNF-α drives the expression of PCSK9 243, or vice versa 
PCSK9 induces TNF-α (Figure 6). In conclusion, in the present study we provided evidence for a 
direct pro-inflammatory effect of PCSK9 on macrophages, a pathophysiological relevance of this 
in vitro observation required further investigations.   
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